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The Na+/H+ Exchanger Regulatory Factor 1 (NHERF1) is a PDZ-domain containing scaffold 
abundantly expressed in epithelial tissues.  Previous reports from our laboratory demonstrate that 
NHERF1 negatively regulates Wnt canonical signaling in breast epithelial cells through its 
interactions with Frizzled receptors.  Parallel studies conducted at that time also suggested that 
NHERF1 knockout mice presented a form of communicating hydrocephalus reminiscent of 
phenotypes associated with mutations in the non-canonical Wnt Planar Cell Polarity (Wnt PCP) 
pathway.  This observation leads to the hypothesis that NHERF1 regulates both canonical and 
non-canonical Wnt signaling and acts as a “signaling switch” between the two pathways. To 
further elucidate the role of NHERF1 in Wnt signaling regulation we proposed three specific 
aims: 1) To demonstrate that NHERF1 can act as a tumor suppressor in a Wnt/β-catenin driven 
breast cancer model, 2) To determine the role of NHERF1 expression and Wnt/β-catenin in 
endocrine resistant breast cancer, and 3) Investigate the role of NHERF1 in the regulation of Wnt 
PCP signaling in the mouse ependyma.  Although the exact role that NHERF1 plays in the 
regulation of Wnt canonical signaling in breast cancer remains elusive, our results indicate that 
NHERF1 increases the association of key Wnt PCP members Van-Gogh like (Vangl) and 
Frizzled (Fzd) and promotes PCP signaling and ciliogenesis in mouse ependymal tissue. 
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1.0  INTRODUCTION 
 
This thesis aimed to further characterize the role of the PDZ scaffold NHERF1 in the regulation 
of Wnt signaling in epithelial tissues; specifically the mammary and ependymal tissues.  This 
chapter will introduce several of the proteins, signaling pathways and pathologies relevant to the 
research discussed in chapters 2 and 3.  
 
1.1 INTRODUCTION TO PDZ PROTEINS  
 
PDZ domains are abundant protein-protein interaction domains named after the first three 
proteins in which they were discovered: PSD-95, Discs-large and ZO-1 [1]. In humans, there are 
approximately 200 proteins that contain PDZ domains and nearly a third of these proteins 
contain more than one.  PDZ domains are typically 80-90 amino acids long and they fold into 
compact globular structures composed of six β-sheets (βA-βF)  and two α-helixes, one short (αA) 
and one long (αB) [2].   Most PDZ ligands are four amino-acid sequences and are located at the 
extreme C-terminus of the target protein; however, internal PDZ ligands upstream of the C-
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terminus have also been described [3].   Ligand residues are typically labeled by their position in 
relation to the C-terminus, where the C-terminal residue is referred to as P0, while subsequent 
residues towards the N-terminus are named P-1, P-2, P-3 etc.  PDZ domains are classified by the 
type of amino acid sequences they typically bind to: Class I PDZ domains interact with proteins 
ending in the consensus sequence –X-3-S/T-2-X-1-ϕ0, where X is any amino acid and ϕ is a 
hydrophobic residue.  Class II domain bind to X-3-ϕ-2-X-1-ϕ0 sequences and class III domains 
prefer to bind to D/E/K/R-2-X-1- ϕ0 motifs [4-6].  As is evident from this classification system, the 
residues that are most critical for PDZ domain recognition are P0 and P-2 [6]. This is due to the 
nature of the interaction between the peptide ligand and the binding site of the PDZ domain.  
The ligand binding site of the domain is located in the groove between the βB and αB, 
and it contains a highly conserved R/K-XXX-G-ϕ-G-ϕ motif [7].  Ligands bind in the extended 
groove between the βB and αB resulting in a “β-strand addition” to the pre-existing β-sheet of 
the PDZ domain [8]. The positioning of the peptide ligand is such that the side chains of residues 
P0 and P-2 point directly into the base of the peptide binding groove. Hydrophobic residues in the 
domain (typically V, I or L) create a hydrophobic binding pocket in the β-sheet and α-helix 
groove [9].  The terminal hydrophobic amino acid of the ligand sits in this hydrophobic cavity 
and mutation of this residue to a hydrophilic amino acid is sufficient to prevent ligand-domain 
interactions [1, 10]. In fact, the ease in which PDZ domain specificity can be altered by single 
substitutions is a hallmark of PDZ interactions.  Class I domains contain a histidine in the area of 
the binding pocket that interacts with P-2, thus favoring serine or threonine residues at that 
position. In class II binding pockets on the other hand, the histidine is replaced by a hydrophobic 
amino acid, resulting in a preference for hydrophobic residues at the P-2 C-terminal position [11, 
12].  PDZ interactions are likely fine-tuned by the specific interactions of residues other than P-2 
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and P0 with amino acids adjacent to the binding groove, thus allowing for specificity between 
PDZ targets [7, 13]. While most PDZ ligands described to date are at the extreme C-terminus of 
the target, internal PDZ motifs have been reported. Internal motifs can be recognized if they 
form a tertiary structure that mimic a C-terminus. For example, PSD95 can interact with nNOS 
via a 30 residue section of the nNOS PDZ domain. The 30-residue ligand adopts an extended β-
hairpin fold, where the normally required C-terminus is replaced by a sharp β-turn [14].   
Studies have reported PDZ-peptide interactions to have binding affinities in the low 
micromolar range (1-10 µM) [15, 16].  These affinities are similar to those of SH2 and SH3 
protein-protein interaction domains; moderate affinities such as these are likely beneficial in 
regulatory functions where strong but transient interactions are necessary.  As mentioned above, 
one of the most noteworthy aspects of PDZ proteins is that several members contain multiple 
PDZ domains in tandem, a characteristic mostly absent in other protein-protein interaction 
domain families. It is of no surprise that these multiple PDZ domain containing proteins often 
serve as scaffolds for multi-protein signaling complexes.   
One example of PDZ proteins functioning as scaffolds is the family of membrane-
associated guanylate kinases, or MAGUKs. MAGUKs typically contain 1-3 PDZ domains along 
with an SRC homology 3 domain (SH3) and a guanylate kinase homology domain (GuK). 
Through these multiple interaction domains, MAGUKs assemble multi-protein complexes 
containing receptors, adhesion proteins and various signaling molecules crucial for proper 
development of the neuronal synapse [17].  The Drosophila protein INAD contains 5 tandem 
PDZ domains and is believed to function as a scaffold for G-protein mediated photo-transduction 
in the eye. INAD interacts with several proteins in the cascade and mutation of INAD results in 
the mislocalization of these proteins and loss of signaling [18, 19]. 
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Aside from multi-protein complex formation, PDZ-containing proteins also play a role in 
the transportation and localization of proteins.  One example is NHERF1, which has been shown 
to regulate membrane protein activity and trafficking (discussed further in following sections).  
In C. elegans, LIN-2, LIN-7 and LIN-10 are PDZ domain containing proteins that form a 
trimeric complex that regulates localization of certain targets.  Mutation of LIN-7 results in loss 
of LET23 (EGFR homolog) membrane localization, and replacement of the binding interaction 
domain of LIN-7 and LET23 with a heterologous binding pair rescues the phenotype [20, 21].   
Overall, several lines of research over the past couple of decades have demonstrated the 
importance of PDZ interactions. PDZ domain containing proteins interact with a wide array of 
proteins, including G-protein coupled receptors (GPCRs), receptor tyrosine kinases, as well as 
ion channels and transporters. Several proteins discussed throughout this thesis partake in PDZ 
protein-protein interactions and determining the role of PDZ domains in the regulation of cell 
signaling is a constant theme throughout the aims presented in this document.  
 
 
1.2 THE PDZ PROTEIN NHERF1  
 
The Na+/H+ exchanger regulating factor 1 (NHERF1), also known as the ezrin binding 
phosphoprotein of 50 kDa (EBP50), is a PDZ domain containing scaffold abundantly expressed 
in the vast majority of epithelial tissues.  NHERF1 was originally identified as an essential 
cofactor for the inhibition of the Na+/H+ exchanger 3 (NHE3) by protein kinase A (PKA) in the 
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kidney [22].  Independent of this observation, another group identified NHERF1 as a 50 kDa 
protein that binds ezrin with high affinity (hence the name EBP50) [23].   Initial reports 
identified NHERF1 as a regulator of the localization, signaling and traffic of  GPCRs, enzymes, 
ion channels and transporters [24].   
 
 
Figure 1. NHERF1 structure and function. NHERF1 contains two tandem PDZ protein-protein interaction 
domains and a C-terminal domain that bind to members of the MERM family (merlin, ezrin, radixin and moesin). 
LEFT: diagram of NHERF1 with examples of PDZ-1 and PDZ-2 binding targets. RIGHT: NHERF1 typically binds 
to targets at the plasma membrane and tethers them to the cytoskeleton via its interaction with ezrin proteins.   
 
1.2.1 NHERF1 function at the cell membrane and cytoskeleton 
NHERF1 contains a C-terminal ezrin binding domain (EBD) and two tandem PDZ domains 
through which it carries out its function (see Fig. 1).  Both of NHERF1’s PDZ domains are class 
I PDZ domains that contain a GYGF binding motif.  Most of NHERF1’s targets interact with the 
first PDZ domain (PDZ-1) and only a few proteins (such as NHE3 and β-catenin) preferentially 
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interact with the second PDZ domain (PDZ-2) [25-27]. Over 30 different proteins have been 
shown to interact with NHERF1, including GPCRs such as the β2-adrenergic receptor (β2-AR), 
the parathyroid hormone type 1 receptor (PTH1R), and the κ-opioid receptor  [24].  Additionally, 
NHERF1 binds to ion channels, such as the cystic fibrosis transmembrane conductance regulator 
(CFTR), and growth factor receptors such as the EGFR and the platelet-derived growth factor 
receptor (PDGFR)[24].      
One of the major proteins NHERF1 interacts with is ezrin, a cytoplasmic protein that 
serves as an intermediate between the plasma membrane and the actin cytoskeleton. Both 
proteins co-localize at the apical membrane of epithelial cells, where they reciprocally stabilize 
one another [28]. Studies have demonstrated that NHERF1 and ezrin deficient animals show 
similar defects in their apical intestinal brush border membrane, implicating NHERF1 and ezrin 
in maintaining the apical structure of polarized epithelial cells [28]. Along these lines, NHERF1 
is believed to function in the stabilization of transmembrane receptors and ion channels at the 
plasma membrane by anchoring/localizing them to the cytoskeleton [29].  Indeed, NHERF1 
expression is thought to increase CFTR conductance by tethering two channels together through 
the tandem PDZ domains, inducing an activating conformational change [30, 31].   Furthermore, 
the apical localization of CFTR and the inward rectifier K+ channel ROMK (renal outer 
medullary potassium channel) is dependent on NHERF1 expression [32]. However, studies have 
demonstrated that several NHERF1 targets can retain their apical localization even in the 
absence of NHERF1 expression, suggesting that some of the localization functions of NHERF1 
are part of a general and redundant role for PDZ proteins [5, 33, 34].   
Several studies indicate that NHERF1 also plays an important role in the trafficking and 
regulation of GPCRs.  The first line of evidence was the observation that NHERF1 expression is 
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required for β2-AR mediated activation of NHE3.  NHERF1 binds to NHE3 and prevents basal 
activation through its interaction with PKA [35]. Upon activation of β2-AR, NHERF1 binds to 
the C-terminus of the receptor presumably out-competing the NHERF1-NHE3 interaction. The 
interaction between NHERF1 and β2-AR is also required for agonist-induced receptor recycling 
[34, 35].  NHERF1 can also tether β2AR and PTH1R receptors to the actin cytoskeleton and 
regulate their distribution [36].  Additionally, NHERF1 inhibits ligand-dependent internalization 
and β-arrestin-independent endocytosis of PTH1R [34, 37, 38]. NHERF1 modulation of PTH1R 
can also increase cyclic AMP (cAMP) and phospholipase C (PLC) activity. The role of NHERF1 
in PTH1R regulation is further supported by the observation that NHERF1 knock out mice 
present severe deficiencies in mineral ion homeostasis and bone density, functions mediated in 
part by PTH1R [39].  NHERF1 can also bind to the κ opioid receptor and increase its recycling 
rate, thus preventing agonist induced down-regulation of the receptor.  Frizzled receptors, 
considered “atypical” GPCRs, can also bind to NHERF1 and this interaction attenuates 
downstream signaling [40].  
The interaction with ezrin and other ERM proteins has a regulatory role on NHERF1 
conformation.  NHERF1 contains a C-terminal PDZ ligand that in the absence of ezrin binds to 
the PDZ-2 domain of the protein, adopting a head to tail conformation that reduces the binding 
affinity of both PDZ domains [41-43]. Studies indicate that the intramolecular interactions 
between PDZ-2 and the EB region compete with PDZ ligands [43]. Ezrin binding displaces the 
C-terminus from the PDZ-2, thus making both PDZ domains available to bind to their ligands 
[44]. This method of regulation may serve as a way to ensure NHERF1 assembles protein 
complexes only when properly localized and attached to the cytoskeleton.   
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1.2.2 NHERF1 oligomerization and phosphorylation  
Several studies indicate that NHERF1 can form homodimers. Two mechanisms of NHERF1 
oligomerization have been observed: head-to-tail dimerization (mimicking NHERF1’s own 
intramolecular regulation) and dimerization of the PDZ domains [41, 45]. It is unclear if 
NHERF1 dimerization occurs in vivo and the precise biological significance of this phenomenon 
is not fully understood [46].  Dimerization of NHERF1 can be regulated by post translational 
modifications.  
NHERF1 is a phospho-protein that contains 31 S/T residues and phosphorylation of 
NHERF1 can modulate its binding affinity for certain targets.  Although purified PKA does not 
phosphorylate either recombinant NHER1 PDZ domains or full length NHERF1 directly, PKA 
induces the phosphorylation of NHERF1 in vivo through increased cAMP concentrations [47]. 
Phosphorylation of the S287, S289 and S290 cluster between PDZ-2 and the EBM by PKA is 
required for NHERF1 biological activity [48]. NHERF1 is constitutively phosphorylated at S289 
by GRK6. Phosphorylation at S289 in rabbit (S290 in humans) is necessary for the assembly of 
NHERF1 oligomers. S77 is located in the PDZ-1 domain and phosphorylation of this residue by 
protein kinase C (PKC) significantly reduces its binding to the β2-AR and the sodium-phosphate 
cotransporter type IIa [47, 49].  PKC phosphorylation of S162 in the PDZ-2 domain attenuates 
NHERF1 binding to CFTR [50].  Furthermore, phosphorylation by PKC at S339 and S340 can 
disrupt the head-to-tail autoinhibitory conformation of NHERF1 [42].  
  
 9 
1.3 WNT CANONICAL SIGNALING 
 
The Wnt signaling pathway is a highly conserved signaling pathway that regulates several 
crucial aspects of embryonic development as well as adult tissue homeostasis [51, 52].    
Comparative genomics revealed Wnt genes can be found in all metazoan organisms, 
underscoring their importance throughout animal evolution [53].  The first two members of the 
Wnt family of genes to be identified were the Drosophila gene wingless (wg), and its vertebrate 
homolog integrated, or int-1.  In 1980, genetic studies in Drosophila revealed that mutations in 
the wg locus resulted in embryonic lethality and patterning defects, identifying the gene as a 
major player in embryonic development [54, 55]. A few years later, Nusse and Varmus 
discovered the preferential integration site for the Mouse Mammary Tumor Virus (MMTV) in 
breast tumors, and therefore named the gene integrated or int-1 [54].  In 1987 wg was shown to 
be a homolog int-1 [56], and shortly thereafter the names of the two genes were fused to “Wnt”.   
Over the past few decades a large body of research has demonstrated that Wnt genes regulate a 
long list of biological processes such as: cell determination, proliferation, motility, polarity, stem 
cell renewal, primary axis formation and organogenesis.  Deregulated Wnt signaling often results 
in fatal developmental defects, and in adults can lead to cancer of the breast, colon and skin [52, 
57]. There are currently three different signaling pathways that are believed to be regulated by Wnt 
family members: the canonical Wnt/β-catenin pathway, the non-canonical planar cell polarity 
pathway (PCP), and the non-canonical Wnt/Ca2+ pathway. As the name would suggest, the 
“canonical” Wnt signaling pathway, which regulates the transcriptional co-activator β-catenin, is 
the best understood of the three and is the primary focus of the following section.   
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1.3.1 Wnt ligand production and secretion 
Wnt family members are defined by amino acid sequence rather than functional properties.  In 
mammals there are 19 different secreted Wnt proteins. These proteins are typically 350-400 amino 
acids long and are characterized by a highly conserved cysteine rich region.  Despite the presence 
of an N-terminal signal sequence which targets the protein for secretion, Wnt ligands are virtually 
insoluble. This unexpected observation is due to the fact that Wnts are palmitoylated at a 
conserved cysteine that is essential for protein function [58].   
The Drosophila gene porcupine (por) is believed to be responsible for the palmitoylation of 
Wnt ligands due to it sequence homology with acyl-transferases [59]. This is supported by the 
observation por is required in Wnt producing cells but not cells that receive Wnt signals [60].  In 
2006, genetic studies in Drosophila revealed that secretion of Wnt proteins depended on a gene 
named wntless (wls), also known as evenness interrupted (evi) [61-63]. The wntless encoded 
protein was found to be primarily localized in the Golgi, and loss of expression retains Wnt ligands 
inside the cell that produces them. Wnt ligand secretion also requires the retromer complex, a 
highly evolutionary conserved multi-protein complex involved in intracellular trafficking [62].  
Tissue staining demonstrates that Wnts form long-range gradients and are believed to 
function as morphogens, meaning that their signaling is long range and concentration dependent 
[64, 65]. How these gradients are formed and regulated is not fully understood.  Cytonemes (long 
and thin filopodial processes) have been speculated to carry Wnts away from signaling cells. One 
other possibility is that palmitoylation of Wnts limits diffusion from membranes and lipid 
particles, tethering Wnts to intercellular transport vesicles and lipoproteins [66].  Additionally, 
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evidence suggests that heparin sulfate proteoglycans (HSPG) may stabilize and transport of 
secreted Wnt proteins in Drosophila [67]. 
1.3.2 Wnt receptors and inhibitors 
In 1996 Frizzled (Fz) was identified as the receptor for Wnt ligands and in humans ten members of 
this family of proteins have been identified.  Fz receptors possess seven transmembrane domains 
and long amino-terminal cysteine-rich domain (CRD). Interestingly, Fz receptors contain both 
internal and carboxy terminal PDZ ligands. Wnt ligands bind directly to the CRD domain of Fz 
with high affinity [68, 69].  Studies in Drosophila and cell culture suggest that Fz receptor 
activation during canonical signaling is ligand-dependent, and overexpression of receptor in the 
absence of ligand is insufficient for signaling activation [68, 70].  In addition to Fz, Wnt ligand 
induced activation also relies on arrow in Drosophila and low-density-lipoprotein-related protein 5 
and 6 (LRP5/6) in vertebrates, both single pass transmembrane receptors required for canonical 
Wnt signaling. In vertebrates Wnt, Fz and LRP have been reported to form a ternary complex, 
suggesting that Wnt ligands may physically mediate the interaction between Fz and LRP5/6 [71].  
In addition to Wnt, the protein Norrin, which shares no sequence homology with Wnt ligands, can 
bind to Fz4 and LRP5/6 to promote canonical Wnt signaling [72].  
Wnt signaling is antagonized extracellularly through a diverse group of Wnt inhibitors: 
secreted Frizzled-Related Protein (sFRPs), Wnt-inhibitory factor-1 (WIF-1), and the Dickkopf 
(Dkk) family of inhibitors are just a few examples [51].  The Dkk family of Wnt inhibitors binds to 
and antagonizes LRP5/6 receptors and are considered specific inhibitors of Wnt/β-catenin 
signaling.  Although some evidence suggests Dkk1 can induce the internalization and degradation 
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of LRP5/6 through its interaction with Kremen proteins [73], the currently more accepted model of 
Dkk1 action is that it disrupts the formation of the Wnt-induced Fz-LRP5/6 complex [74, 75].  
SOST, another LRP5/6 antagonist, is also believed to function through this mechanism [76].  
WIF and sFRPs bind to Wnt and, in the case of sFRPs, also to Fz, thereby antagonizing both 
canonical and non-canonical Wnt signaling. Genetic studies in mice indicate significant 
redundancy of sFRPs [77], and some sFRPs have been shown to possess Wnt-independent activity 
such as regulation of axon guidance and proteinase inhibition [78]. Shisha proteins are a distinct 
family of Wnt antagonists that trap Fz protein in the endoplasmic reticulum and prevent 
localization of the receptor to the cell surface [79].  
1.3.3 Wnt deactivated state 
In the absence of Wnt, β-catenin is negatively regulated by glycogen synthase kinase 3 (GSK3) 
and casein kinase I α (CK1α), resulting in reduced β-catenin stability.  GSK3 does not bind to β-
catenin directly and requires the expression of the protein Axin and adenomatous polyposis coli 
gene products (APC), which along with CK1, are now known as the “β-catenin destruction 
complex”. APC and Axin bind to β-catenin, GSK3 and CK1, promoting their interaction and 
subsequent phosphorylation of β-catenin [51]. The phosphorylation of β-catenin happens in a 
sequential manner; first CK1 phosphorylates at the single site S45, and then GSK3 phosphorylates 
β-catenin at T41, S37, and S334 [52]. N-terminal phosphorylation of β-catenin promotes its 
interaction with β-TrCP/Slimb, a component of the SCF ubiquitin ligase complex.  This ultimately 
leads to the ubiquitination of β-catenin and its subsequent degradation by the proteasome [80]. 
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Axin and APC are both tumor suppressors critical for β-catenin regulation.  Axin is thought to 
act as a scaffold, and it is the only protein that can interact with all other members of the 
destruction complex [81]. Additionally, quantitative analysis suggests that the association of Axin 
is the rate limiting step in the assembly of the destruction complex due to its low levels of 
expression compared to other members [81, 82].   
The precise role of APC in β-catenin regulation remains uncertain. Studies have demonstrated 
that both APC and Axin can be phosphorylated by GSK3 and CK1, and these modifications lead to 
increased affinity for the same domain of β-catenin [80, 81]. This observation led to the hypothesis 
that APC functions by removing phosphorylated β-catenin from Axin, increasing β-catenin 
turnover and allowing Axin to participate in another round of β-catenin phosphorylation [80]. 
Consistent with this model, overexpression of Axin in cancer cells that do not express APC 
restores β-catenin inhibition, suggesting that APC is only necessary when Axin levels are low.  
Interestingly, APC can actually promote Wnt signaling in vivo by enhancing Axin 
degradation, a function dependent on the N-terminal portion of APC which is not involved in β-
catenin degradation [81, 83].  One explanation for this paradoxical observation is that it helps 
buffer dramatic changes in β-catenin when APC levels vary; a decrease in APC would then result 
in increased Axin levels, thereby compensating for decreased β-catenin degradation [81].  Colon 
cancer cells often retain the N-terminal half of APC and could potentially use this portion to 
further enhance β-catenin signaling [84-86].   APC has also been shown to function in the 
nucleus to promote β-catenin nuclear export and act as a suppressor for β-catenin target genes 
[87]. 
Further regulation of the destruction complex can be mediated by two S/T phosphatases, 
PP1 and PP2A.  PP1 dephosphorylates Axin, promoting the dissociation of the Axin complex 
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[88].  PP2A can dephosphorylate β-catenin, and evidence suggests APC can protect β-catenin 
from its activity [89].  How the activity of these phosphatases is regulated by Wnt signals has yet 
to be determined. 
1.3.4 Wnt activated state 
Wnt-mediated activation of β-catenin occurs after Wnt ligands bind simultaneously to Frizzled and 
the co-receptors LRP5/6. This is hypothesized to result in the formation of large protein complexes 
dubbed “signalosomes” at the plasma membrane, which are believed to be the critical first step in 
subsequent Wnt signaling transduction.    
According to the signalosome hypothesis, ligand binding to Fz and LRP receptors promotes a 
clustering of these receptors that recruits the cytoplasmic phosphoprotein Dishevelled (Dvl) to the 
plasma membrane [90]. Dvl is a PDZ domain containing protein; surprisingly the Fz-Dvl 
interaction is mediated by an internal PDZ ligand, despite the presence of C-terminal PDZ ligands 
in 8 of the 10 human Frizzled receptors [91]. Dvl also contains a highly conserved DIX domain 
that it shares with the protein Axin, and this domain mediates a reversible head-to-tail 
polymerization crucial to Dvl signaling activity [92]. Wnt activation of receptors triggers the 
polymerization of Dvl [93].  Polymerization of Dvl allows the protein to co-polymerize with Axin 
via their shared DIX domains, thus recruiting it (and associated proteins) to the plasma membrane 
to form part of the signalosome [94].  Further signaling requires the phosphorylation of LRP5/6.  
LRP5/6 receptors contain five repeats of PPPSPxS motifs, which upon phosphorylation can 
serve as docking sites for the Axin complex. Remarkably, knock out studies revealed that the main 
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kinase responsible for LRP6 phosphorylation at PPSP sites is Axin-bound GSK3 [95, 96], making 
GSK3 both a positive and negative regulator of β-catenin signaling.   
Once the PPSP motifs of LRP5/6 have been phosphorylated, this primes the receptor for 
further phosphorylation. Clustered Dvl promotes phosphorylation of LRP6 by CK1γ and CK1ε at 
adjacent S sites (PPPSPxS) [97], which is crucial for the functioning of the signalosome [90, 96].  
It is interesting to note that this phosphorylation sequence is the opposite of the one for β-catenin, 
where CKIα primes the protein for GSK3 phosphorylation. Once LRP6 is fully phosphorylated the 
PPPSPXS sites serve as loading docks for Axin, which recruits the β-catenin destruction complex 
[98].  The fact that Axin is recruited by Dvl and required for LRP phosphorylation, and that in turn 
LRP phosphorylation recruits Axin, suggests a positive feed-forward loop in Wnt/β-catenin 
signaling that ensures phosphorylation of all five PPPSPxS motifs. This idea is supported by the 
observation that LRP6 activity is particularly sensitive to PPPSPxS copy number [99].  
How signalosomes inhibit phosphorylation of β-catenin by GSK3 is not fully understood. In 
2006, Mi and colleagues reported that GSK3 can bind directly to the cytoplasmic tail of LRP6 and 
phosphorylate it [100]. Shortly after this discovery, it was reported that phosphorylation of LRP6 
at PPPSPxS motifs is crucial for GSK3 inhibition [101]. Additionally, dually phosphorylated 
PPPSPxT peptides were shown to be sufficient to inhibit GSK3 kinase activity towards β-catenin 
and other targets in vitro and in vivo [102, 103].  Taken together, these observations suggest that 
the phosphorylated LRP motifs may act as pseudo-substrates for GSK3, competitively inhibiting 
its interaction with β-catenin. This particular model also fits well with previous observations of 
GSK3 regulation by Akt, which phosphorylates GSK3 at the N-terminus, creating a pseudo-
substrate (phospho-S9-GSK3) that is thought to fold back into the catalytic pocket of GSK3 [104].   
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A fairly recent study published in 2010 proposes a different model describing how Wnt 
canonical signaling may decrease GSK3 activity through the sequestration of the enzyme from its 
substrates in internal membranes [105].  The study demonstrates that Wnt canonical signaling 
activity results in internalization of GSK3β (and other components of the signalosome) in 
multivesicular bodies (MVBs). Consequently, GSK3 can no longer interact with newly synthesized 
β-catenin. This is supported by the observation that cell extracts solubilized with Triton X-100 did 
not contain Wnt-inhibited GSK3, while cell extracts solubilized with digitonin (which does not 
solubilize intracellular vesicles) showed a Wnt induced 66% decrease in GSK3 activity.  However, 
an alternative explanation is that Triton X-100 may have a binding affinity to the signalosome 
complex itself.  Furthermore, the authors were unable to detect a reduction in endogenous GSK3β, 












Figure 2. Wnt Canonical Signaling.  In the absence of Wnt ligands, the N-terminus of β-catenin is hyper-
phosphorylated by the β-catenin destruction complex, which targets the protein for proteasome degradation.  The 
destruction complex is composed of the scaffold protein Axin, the tumor suppressor APC, and the kinases CK1 and 
GSK3.  In the presence of Wnt ligands, Wnt binding increases the association of Fzd and LRP5/6 receptors, which 
recruits the cytoplasmic protein Dvl. Dvl polymerization induces GSK3 and CK1 dependent phosphorylation of 
LRP5/6, which results in decreased degradation of β-catenin and increased β-catenin nuclear localization.  Once in the 
nucleus, β-catenin binds to TCF transcription factors to regulate TCF/LEF target genes.  
 
1.3.5 β-catenin in the nucleus  
The decreased phosphorylation of β-catenin following canonical Wnt signaling activation leads to 
increased stability of the protein and translocation to the nucleus. The precise mechanism by which 
β-catenin is shuttled to the nucleus remains unknown. β-catenin nuclear import does not depend on 
the Nuclear Localization Signal/importin machinery, and it has been proposed that β-catenin enters 
the nucleus through direct interaction with nuclear pores [107].  Some evidence suggests that two 
proteins, TCF and Pygopus, can promote β-catenin nuclear localization, however β-catenin can 
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still localize in the nucleus in the absence of either protein [108]. β-catenin can also be exported 
from the nucleus by APC or Axin [107, 109].   
Once in the nucleus, β-catenin forms complexes with members of the TCF/LEF family of 
transcription factors. Vertebrates have four TCF/LEF genes that differ dramatically in their 
sequence, yet are biochemically similar and were found to be largely redundant in knockdown 
studies [110]. In the absence of Wnt, TCF associates with Groucho (TLE1 in humans), which 
promotes chromatin compaction to repress Wnt target genes [111]. Upon Wnt activation, β-catenin 
binds to TCF, displacing Groucho/TLE1 and recruiting the histone acetylase and co-transcriptional 
factor CBP/p300.   
The association of β-catenin to TCF is thought to create a bipartite transcription factor in 
which TCF is the DNA binding domain and the C terminus of β-catenin is the transactivation 
domain. β-catenin and TCF bind to DNA consensus sequences CCTTGWW (W represents either T 
or A), referred to as Wnt responsive elements (WREs), inducing DNA bending and chromatin 
remodeling conducive to transcriptional activation.  The nuclear antagonists Chibby and ICAT 
bind to β-catenin and disrupt β-catenin/TCF and β-catenin/co-activator complexes, resulting in 
increased nuclear export of β-catenin [112, 113]. Additionally, TCF/LEF transcription factors can 
be inhibited through post-translational modifications including phosphorylation, acetylation, 
sumoylation and ubiquitination.  
1.3.6 Wnt signaling in cancer 
Many proto-oncogenes encode components of growth signaling pathways. β-catenin 
transcriptional activation produces changes in gene expression that can result in transformation and 
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loss of epithelial phenotype. Some of these targeted genes are developmental regulatory genes 
such as siamois, twin and Xnr-3 in Xenopus.  Additional targets include regulators of cell growth 
and proliferation: c-myc and cyclin D1 [114, 115].  C-myc is a powerful oncogene that promotes 
cell cycle progression by inducing G1/S phase transition and its expression is promoted by Wnt 
ligands.  DNA microarray analysis revealed several other genes regulated by β-catenin/TCF that 
are implicated in the proliferation and differentiation of cells, including: c-myb, ets, bmp4 and 
ephrin receptors EPHB2 and EPHB3 [116]. Studies in colorectal carcinomas confirm the 
generalization that β-catenin/TCF targets often work to repress differentiation and induce 
proliferation [117].  
Wnt signaling deregulation in colorectal cancer has been well documented. The first piece 
of evidence was the discovery that germline mutations in APC were the cause of Familiar 
Adenomatous Polyposis (FAP) in 1991.  FAP is a hereditary cancer characterized by the 
development of a large number of colon polyps early in life [118, 119].  While FAP patients inherit 
only one mutant APC allele, eventually loss of the second allele occurs in some cells leading to the 
development of malignant carcinomas.  The role of APC as a tumor suppressor in the colon was 
further supported by studies that demonstrated that a vast majority of spontaneous colorectal 
cancers lose both APC alleles [120].  Over 80% of colorectal cancers harbor mutations for APC, 
and over 300 different disease associated mutations of APC have been identified [85].  Inactivating 
mutations of APC increase β-catenin stabilization and protein levels [121]. In the small percentage 
of colon cancers without APC mutations, mutations in other members of the Wnt/β-catenin 
signaling pathway have been found: mutations in Axin2 [122], and activating mutations of β-
catenin [84].   
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Activating mutations of the Wnt pathway can also be found in other types of sporadic 
tumors. Many upper gastrointestinal tumors contain mutations of β-catenin and APC genes [123-
126].  Furthermore, deregulation of Wnt signaling has been implicated in the development of hair 
follicle tumors, or pilomatricomas.  Several studies have reported activating mutations of β-catenin 
in the majority of spontaneously occurring human pilomatricomas [127-129]. Transgenic mice that 
express stabilized β-catenin develop lesions similar to human epithelial cysts and pilomatricomas 
[130].   
Wnt signaling has also been implicated in the development of hepatocellular carcinoma 
(HCC), which accounts for 75% of all liver cancers [131].  Indeed, one of the first studies 
suggesting the role of Axin as a tumor suppressor came from a report that demonstrated 
inactivating mutations of AXIN1 in HCC [132]. Several studies have looked at β-catenin gene 
(CTNNB1) mutations in HCC; collectively, these reports show that approximately 20% of HCC 
carcinomas harbor activating mutations of β-catenin [132-137].  One study suggests that mutations 
in β-catenin are more common in HCCs associated with hepatitis C infections (41%) [138].  
Furthermore, the expression of nuclear β-catenin has been demonstrated to be significantly 
correlated with patient clinical outcome [136].  
Reproductive organs are also prone to cancers characterized by upregulated Wnt signaling. 
Nuclear expression of β-catenin was identified in approximately 30% of endometrial-type ovarian 
cancers. Moreover, sequence analysis identified CTNNB1 mutations in 28% of primary tumors 
[136, 139-143]. Furthermore, mutations in APC and AXIN1/2 have also been reported in 
endometrial-type ovarian carcinomas [141]. One study also reported increased nuclear β-catenin in 
37% of cervical cancers [144].  Finally, three different groups have collectively reported a small 
(5%) but noteworthy presence of CTNNB1 mutations in prostate cancer [145-147].  
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Several studies suggest a role for Wnt canonical signaling in mammary development and 
carcinogenesis in animal models. One of the first pieces of evidence indicating that deregulated 
Wnt signaling can lead to carcinogenesis was the observation that mice ectopically expressing 
Wnt-1 developed mammary tumors [148]. Others have reported amplification of the Wnt-2 gene in 
mice mammary tumors [149].  TCF1 knock out mice eventually develop adenocarcinomas in the 
intestines and mammary glands [150]. Furthermore, transgenic mice with mammary-specific APC 
mutations and mice overexpressing Axin have defects in mammary and lymphoid development 
[151, 152].  Surprisingly, very few if any mutations of CTNNB1, APC or AXIN genes have been 
found in human breast cancer [153-155].  One study did report identifying APC mutations in 18% 
of primary breast cancer samples screened, however most of these mutations were downstream of 
the cluster region for APC truncations associated with constitutive activation in colon cancer, so 
the status of APC function in the samples was unknown [156].  
Nevertheless, increased nuclear β-catenin has been reported in 60% of human breast cancer 
samples and it is significantly correlated with poor prognosis [157]. Moreover, some reports 
indicate overexpression of WNT-2, WNT-5A and WNT 7B ligands in some breast cancer tumors 
and cell lines [158-161]. Together, these observations indicate that despite the lack of Wnt gene 
mutations identified in human breast cancer, upregulation of the pathway through ligand 
overexpression or some other unidentified means could be contributing to mammary 
carcinogenesis. Our laboratory recently published findings that implicate the PDZ scaffold 
NHERF1/EBP50 in the regulation of Wnt canonical signaling [40].  NHERF1 is highly expressed 
in mammary tissue and is regulated by estrogen [162, 163].  NHERF1 and other atypical regulators 
of Wnt signaling yet to be identified could potentially play a role in the regulation of canonical 
Wnt signaling in the breast, thus explaining the lack of Wnt mutations identified in breast cancer. 
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Hopefully, future studies will be able to further elucidate the role of Wnt canonical signaling in 
human breast cancer.  
 
1.4 WNT PLANAR CELL POLARITY SIGNALING 
 
The Wnt/Planar Cell Polarity pathway is one of the “non-canonical” branches of Wnt signaling 
and its transduction is independent of β-catenin activity. Planar cell polarity (PCP) refers to the 
polarization of cells within the plane of the epithelial tissue (perpendicular to the apical-basal axis), 
and its regulation differs from that of apical-basal polarity [164, 165]. Examples of PCP include 
the uniform alignment in proximal-to-distal orientation of the bristles at the apical surface of wing 
cells in Drosophila, and the uniform medial-to-lateral orientation of stereociliary bundles in the 
Corti organ (a mammalian auditory sensory organ). PCP is essential for a variety of developmental 
events involving cell fate decisions, morphogenesis and organized cell movement.  
Wnt/PCP signaling has been shown to be critical for several processes in development, 
including gastrulation, neural tube closure, as well as ear patterning and hearing. Despite the 
importance of PCP, we know very little about this signaling pathway (compared to the breadth of 
information available on Wnt/β-catenin signaling). Most of what we know about PCP signaling is 
through the manipulation of gene expression in animal models. However, the underlying molecular 




1.4.1 Wnt PCP signaling in development 
Extensive genetic studies in Drosophila identified a set of six genes indispensable for proper 
PCP in adult fly tissues: Frizzled (Fz), Flamingo (Fmi,), Strabismus (Stbm, also known as Van 
Gogh or Vang), Prickle (Pk), Dishevelled (Dsh,) and Diego (Dgo). Fz, StbM and Fmi are 
transmembrane proteins; their vertebrate homologs are Fzd, Vangl (Van Gogh-like) and Celsr 
(Cadherin EGF LAG Seven-Pass G-Type Receptor 1) respectively; of these receptors Vangl and 
Fz contain class I PDZ ligands that can potentially interact with NHERF1.  Prickle, Dsh (Dvl in 
vertebrates) and Dgo (Dishevelled associated activator of morphogenesis, Daam1, in vertebrates) 
are cytoplasmic proteins. These proteins are thought to be the “core” PCP signaling components 
[164, 166]. Two of these components, Fz and Dsh, are shared with the canonical Wnt pathway.  
In Drosophila the proteins Inturned, Fuzzy and Fritz have been implicated as downstream 
effectors of PCP signaling [166, 167].  Mutation of any of these genes results in disorganized 
bristle and hair growth. Interestingly, Wnt ligands were not found to be necessary for PCP in 
Drosophila, yet “non-canonical” Wnt ligands have been implicated in PCP signaling in 
vertebrates [168, 169].  
 Studies in Drosophila lead to the observation that PCP molecular events often begin with 
the asymmetric localization of Fz, Vang and Dsh proteins at the cell surface. How PCP is 
initiated is still not fully understood. One hypothesis states that the first directional cue for 
polarization is regulated by the atypical cadherins Fat (Ft) and Dachsous (Ds), which are thought 
to act together with the Golgi protein Four-jointed to polarize Fz signaling [170].  Alternatively, 
others have proposed that an unidentified morphogen acts in parallel to Fj, Ds and Ft to localize 
the PCP receptors [171]. The fact that Wnt ligands (Wnt5a and Wnt11) are necessary to mediate 
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certain PCP events in mice also supports the idea that a morphogen gradient may act to localize 
the core PCP receptors. Nevertheless, Ft and Ds asymmetric localization appears to induce 
microtubule alignment in a proximal-distal orientation at the apical surface of the cell [171, 172]. 
Asymmetric distribution of Wnt PCP receptors is transient and precedes major 
morphologic events. In the fly, Vang-Pk complexes localize in the proximal side of the cell and 
Fz, Dsh and Dgo proteins localize distally immediately preceding the initiation of hair growth in 
the wing [173]. The transmembrane protein Fmi is localized both proximally and distally during 
initial PCP events and is thought to mediate PCP by participating in homophilic interactions 
between cells (where one adhesion molecule binds to another of the same kind) and participating 
in the asymmetric localization of Vang and Fz, thereby communicating the PCP signal between 
the cells in a tissue [174]. Additionally, Vang has been reported to interact with Fz 
heterophilically between cells, providing further communication between cells on the tissue 
plane [175].  
Wnt/PCP signaling has been demonstrated to be crucial for proper convergent extension 
in vertebrates. Convergent extension (CE) is a morphogenetic process by which cells “crawl” 
between one another, forming a long narrow array. This process is thought to be mediated by 
polarized lamelipodia (actin-rich protrusions that generate traction for cell movement) [176, 
177].  In Xenopus, the loss of Dvl results in the randomized orientation of  lamelipodia, resulting 
in failed CE [178].  Proper CE is crucial for spinal cord closure and mutation of PCP components 
in mice often lead to tube closure defects.  For example, the classical mutation of Vangl in mice, 
Looptail, results in defective neural tube closure and a “looped tail” appearance [179, 180].  In 
2002, time lapse studies in Xenopus demonstrated that PCP dependent CE was required to close 
the distance between the neural folds of the spinal cord [178]. Shortly after this discovery, Dvl, 
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Celsr, and Fz were also reported to be necessary for proper closure of the neural tube in mice 
[181, 182].   
Wnt PCP signaling is also critical in organogenesis.  Expression of Vangl1, Vangl2, Dvl2 
and Dvl3 are all critical in heart looping and chamber formation and loss of any of these proteins 
leads to cardiac abnormalities [183-185]. Mutation or loss of Wnt5a and Vangl2 alleles leads to 
defects in the formation of the forestomach in mice [186]. Looptail Vangl2 mutant mice also 
present defects in the uterus and vagina, including: short uterine horns, failure of uterine horns to 
fuse at the cervix, and imperforate or septate vaginas [187].  Additionally, loss of Wnt9a leads to 
formation of kidney tubules with abnormally large diameters and eventual kidney cyst formation 
[188]. Furthermore, Celsr1 and Vangl2 are required for the proper branching in the mouse lung 




Figure 3. Wnt Planar Cell Polarity signaling. Extensive genetic studies have identified the following core essential 
components of Wnt planar cell polarity signaling: Fzd, Vangl, Dvl, Daam1, Celsr and Pk.  Expression of these proteins 
leads to downstream activation of Rho/Rac GTPases and JNK, resulting in actin polymerization and cytoskeletal 
rearrangement.  
 
1.4.2 Wnt/PCP signaling in ciliary function 
Cilia are organelles that project from almost all animal cells and their functions include: 
mechanosensation by primary cilia and the induction of directional flow of fluid by motile cilia. 
Ciliopathies include polycystic kidney disease, Bardet-Bidel syndrome (BBS), Meckel-Gruder 
syndrome, and orofaciodigital syndrome amongst others [191]. One of the first indications that 
 27 
PCP signaling could play a role in ciliogenesis was the observation that mice with mutations in 
genes linked to human BBS, a disorder associated with dysfunction of primary cilia, showed 
defects in neural tube closure and misalignment of hair cells in the cochlea [191]. Another clue 
was the similarity in sequence between Dgo/Daam1 and Inversin, a protein critical for cilia 
function.   
Loss of Inversin in zebrafish and Xenopus revealed that the protein is also critical for CE.  
Interestingly, Vangl2 and Dvl both localize near cilia bodies in vertebrate cells [192, 193].  Dvl 
interacts with Daam1, a formin protein that regulates the formation of actin filaments, to 
polymerize actin and regulate its distribution. As one may expect, actin filaments are required for 
the proper positioning of ciliary bodies, and in cells where the actin cytoskeleton is disrupted 
cilia can be found in the cytoplasm of the cell [194, 195].  Furthermore, loss of Dvl3 in Xenopus 
results in decreased number and size of cilia in multiciliated epithelial cells [196]. Knockdown of 
the PCP effectors Inturned or Fuzzy in Xenopus has been reported to result in reduced 
ciliogenesis and reduced actin polymerization [193].  
In the inner ear, mechanosensory hair cells can be found in the organ of Corti, which is 
responsible for the recognition and transmission of auditory signals. Mechanosensory hair cells 
consist of bundles of stereocilia that protrude from the luminal surface of the cell. These bundles 
must be aligned and oriented in one direction for proper function. In Vangl2 Looptail mutants, 
hair cell orientation in the organ of Corti is completely randomized, furthermore, Fzd3 
expression at the membrane is abrogated in these cells [182, 197].  Mutation of Celsr leads to a 
similar phenotype in mice characterized by loss of Vangl2 polarization in the organ of Corti 
[198].  
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Loss of PCP signaling has been shown to impair the function of motile cilia. More 
recently Vangl2 has been shown to regulate the posterior tilting and organization of motile cilia. 
Although Vangl2 mutants can form cilia, the orientation of the cilia is disorganized, resulting in 
lack of directional flow [199]. Knockdown of Celsr2 & Celsr3 in mice results in impaired 
ciliogenesis in the ependymal layer of the brain, resulting in a form of communicating 
hydrocephalus that leads to pathological accumulation of cerebral spinal fluid in the brain [198]. 
It has been speculated that mutation of other PCP components do not inhibit ciliogenesis due to 
the inherent redundancy within each protein family, as evident by the fact that single Celsr 
knockdown causes a much milder hydrocephalus phenotype [198]. Others have reported that 
cilia-generated flow can feed back to fine tune the direction and orientation of cilia in Xenopus, 
and that Wnt PCP signaling may be involved in this feedback signal [200, 201].  
1.5 ESTROGEN SIGNALING AND BREAST CANCER 
 
Estrogen, or 17β-estradiol (also known as E2), is a steroid hormone that is characterized by three 
conjugated aromatic rings. E2 plays a significant role in reproductive function and mammary 
gland development.  Approximately 70% of all diagnosed breast cancers express the estrogen 
receptor (ER), and these cancers depend on estrogen for growth and proliferation. Estrogen 
signaling involves both genomic (nuclear) and non-genomic (extra-nuclear) pathways. In the 
genomic pathways, ligand bound ER dimers regulate target gene expression through direct 
interactions with DNA. Non-genomic estrogen signaling involves the rapid and transient 
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activation of several kinase cascades mediated by translocation of ERs to the cytoplasmic side of 
the cell membrane.   
There are two subtypes of ER, ERα and ERβ. Experimental and clinical evidence 
suggests that the ERα subtype is the main mediator of signaling for the majority of breast cancers 
[202, 203].  In this section, I will introduce E2 signaling with emphasis on its role in mammary 
gland development and breast cancer. 
 
 
Figure 4. ERα structure. A/B: a modulatory N-terminal domain that is also known as the activation function 
domain 1 (AF1). Domain C is a highly conserved DNA binding domain (DBD) located near the center of the 
receptor. The D domain, also known as the “hinge region”, is a highly flexible region which contains a nuclear 
localization signal that becomes exposed upon ligand binding.  Following the hinge region is the E domain, or the 
ligand binding domain (LBD), which contains the hormone binding pocket.  The C terminal region of ERα contains 
the F domain which is necessary for gene modulation and receptor dimerization. The E and F domains are also 




1.5.1 ER signaling in mammary development  
The importance of ERα in the post-natal development of mammary gland was first demonstrated 
in ER receptor knockout studies in mice [204]. At birth, the mammary gland is underdeveloped.  
On the onset of puberty, E2 and progesterone initiate the maturation of the mammary gland 
together [205]. E2 signaling triggers ductal elongation during puberty and knockout of ERα 
(which mediates E2 actions in mice) results in an undeveloped ductal system that fails to branch 
out [206]. In ERα null mice, ducts failed to invade into the fat pad beyond the nipple. Evidence 
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suggests that ERα not only regulates ductal morphogenesis during puberty, but also 
alveleogenesis during pregnancy and lactation [207, 208]. ERβ knockout mice however show no 
difference in mammary gland morphology or development when compared to wild-type, 
indicating that ERα is the ER subtype responsible for regulating mammary gland development 
[209]. Interestingly, ERβ can inhibit the ERα mediated proliferation of breast cancer cells [210].  
1.5.2 ERα genomic signaling  
In the absence of ligand, ERα is sequestered in complex with an inhibitory heat shock protein in 
cell nuclei. Ligand binding induces a conformational change within the ER that induces 
dissociation from chaperone proteins and promotes homo-dimerization. The ER dimers can bind 
directly to DNA with high affinity to specific sequences termed estrogen response elements 
(EREs), which are cis-acting enhancers located within the regulatory regions of target genes 
[211]. The first ERE was initially identified in the estrogen responsive sequence of the 
vitellogenin A2 promoter in Xenopus laevis [212]. In humans, the ERE sequence is a 15bp 
palindrome consisting of two GGTCA half sites separated by a 3 bp spacer; however, ERα can 
also bind to imperfect or half-ERE sites. Binding of the ER to these sequences can either 
enhance or inhibit the transcriptional activity of the downstream target gene. One study 
demonstrated that only a small fraction of ERα binding sites are located in the promoter regions 
but instead are found at relatively long distances from target genes [213].  
For genes lacking functional ERE sequences, ER can activate transcription indirectly through 
protein-protein interactions with other DNA-bound transcription factors. Approximately 35% of 
human E2-responsive genes are activated via ER-indirect DNA association [214].  Some of the 
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major co-transcription factors involved in E2 signaling are Stimulating protein-1 (Sp-1), nuclear 
factor-κ B (NF-κB), and activator protein 1 complex (Ap-1). Sp-1 is responsible for the E2 
mediated induction of low-density lipoprotein (LDL) receptor [215], endothelial nitric oxide 
synthase (eNOS) [216], cyclin D1 [217], and c-Myc amongst many others [218].  Activated ER 
enhances the binding of Sp-1 to GC-rich sequences in the promoters of target genes, recruiting 
co-activators and initiating transcription [219]. NF-κB transcription factor regulates genes 
responsible for inflammation and immune responses. ERα prevents NF-κB stimulated 
transcription of genes, such as interleukin-6 (IL-6), via its interaction with the c-rel subunit of the 
NF-κB complex [220]. AP-1 is actually a complex of several proteins (including fos, jun, and 
others) that regulates genes involved in growth, differentiation and development. AP-1 is 
required for E2 mediated induction of insulin-like growth factor I (IGF-I), ovalbumin, 
progesterone receptor, and ps2/TFF1 [218].  
Over the years several more co-regulatory proteins for ER have been identified, including 
co-activators and co-repressors. Co-regulators often contain Leucine rich motifs (LXXLL, where 
X is any amino acid) that interact with the ligand binding domain of ERα [221]. Most of these 
co-regulators are associated with various enzymatic properties that regulate chromatin 
remodeling, such as: acetyltransferases, deacetylases, methyltransferases, phosphokinases, 
ubiquitin ligases, and ATPases. Therefore, it is generally believed that ERα co-regulators 
promote ER signaling by stabilizing the formation of transcription initiation complexes [222-
224]. For example, CBP and p300 acetylate histones at ERα target gene locations, thereby 
facilitating chromatin remodeling and recruitment of transcription initiation complexes [224]. 
The Switch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex has also been 
demonstrated to regulate ERα transcription [225].  
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Many of the ERα target genes are believed to contribute to oncogenesis. Some of the first 
ERα regulated genes identified in breast cancer cells were pS2TFF1, c-myc, and cyclin D1 [226-
228]. How pS2/TFF1 contribute to breast cancer pathology is not fully understood, however 
others have reported that over expression of pS2/TFF1 in MCF-7 cells is associated with 
increased cell proliferation, migration and motility [229].  Furthermore, pS2 expression is higher 
in transformed cells positively correlated with ERα status in breast tumor samples [230, 231]. 
Cyclin D1 and c-myc are powerful oncogenes (also regulated by Wnt/β-catenin signaling as 
mentioned in the previous sections) that promote cell cycle progression and cell proliferation. 
Mammary specific overexpression of cyclin D1 results in the development of mammary 
carcinomas [232]. ERα can also regulate cell cycle progression by repressing p27, an inhibitor of 
cyclin-dependent kinase 2 (CDK2), resulting in increased CDK2 activity and G1/S progression 
[233].   
Other ERα target genes implicated in breast cancer include: FOXM1, Efp, PELP1, CIZ1 
and GREB1 amongst others. FOXM1 plays a key role in cell cycle progression and its expression 
is increased in the S and G2/M phases of the cell cycle [234].  FOXM1 is believed to mediate 
mitotic division and is upregulated in breast cancer. Efp (estrogen-responsive finger protein) is 
an ubiquitin ligase that promotes breast cancer progression by targeting 14-3-3δ for degradation, 
a protein which inhibits cell cycle progression [235, 236].  PELP1 (proline, glutamic acid, and 
leucine-rich protein) is a co-activator of ERα believed to increase cell proliferation. CDKN1A-
interacting zinc finger protein 1 (Ciz1) is also an ERα co-activator and along with PELP1 is 
positively regulated by E2 signaling, thus their over expression confers hyper-sensitivity to E2 in 
breast cancer cells [237-239].  Ciz1 is believed to promote the interaction between ligand bound 
ERα and target genes. GREB1, or growth regulation by estrogen in breast cancer 1, is another 
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ERα target gene that increases cell proliferation in breast cancer cells [240]. The metastasis-
associated protein 3 (MTA3) promotes epithelial-mesenchymal transition (EMT) and metastasis 
in breast cancer tumors [241, 242].  
Aside from the target genes themselves, several co-regulators of ERα genomic activity 
are known to be de-regulated in breast cancer. Overexpression of amplified in breast cancer 1 
(AIB1), breast carcinoma amplified sequence 3 (BCAS3), MUC1 and several other ER co-
activators have been linked to either breast carcinogenesis or tamoxifen resistance [243-246].  
AIB1 interacts with ERα in a ligand-dependent manner and aids in the recruitment of histone 
acetyltransferases such as p300 and P/CAF to target gene chromatin [247]. BCAS3, also recruits 
p300 and CBP and is dependent on PELP1 function [232]. MUC1 is a transmembrane 
glycoprotein normally localized on the apical surface of secretory mammary epithelium that also 
serves as a potent co-activator of ERα signaling. MUC1 binds to the DNA binding domain of 
ERα stabilizing its expression and blocking its degradation in breast cancer cells [248].  
Co-repressors of ERα signaling are also de-regulated in breast cancer. Typically, co-
repressors counterbalance the action of ER co-activators by recruiting histone deacetylases 
(HDAC) and promoting chromatin condensation. Therefore, loss of co-repressor expression 
promotes breast cancer progression [249]. Repressor of ER activity (REA) and nucleosome 
remodeling histone deacetylation complex (NuRD) both function as HDACs and their de-
regulation results in an invasive cancer phenotype and increased ERα expression [250, 251].  
Nuclear receptor corepressor 1 (NCOR1) inhibits ERα by binding to the ligand binding domain 
of the receptor  and reduced expression of NCOR1 is associated with shorter relapse-free periods 
and decreased survival in breast cancer patients [252]. Furthermore, decreased NCOR1 
expression has been implicated in acquired tamoxifen resistance [253].  
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1.5.3 Non-genomic ER signaling  
While the majority of ER is localized in the nucleus, several lines of research have revealed that 
ER can function outside the nucleus in “non-genomic” ER signaling pathways. Palmitoylation of 
ERα at cysteine 447 localizes the receptor to the plasma membrane and upon ligand binding 
activates MAPK and PI3K/AKT signaling cascades in breast cancer cells [254].  Further 
activation of these pathways can result from E2-mediated activation of various growth factor 
receptors such as IGF-1 and epidermal growth factor receptor (EGFR) [255].  Studies have 
reported that inhibition of MAPK signaling results in significantly reduced cell proliferation and 
tumor growth, suggesting that ERα/MAPK signaling is crucial to breast cancer progression. 
Similarly, PI3K inhibition by LY294002 blocked ERα mediated breast cancer cell migration 
[256]. Furthermore, E2 can induce Bcl-2 activity through both the Ras/PI3K/AKT and 
Ras/ERK/p90RSK1 pathways, thus suppressing apoptosis [257].  
 Recent evidence suggests that ERα genomic co-regulators can also regulate non-genomic 
signaling. PELP1, for example, can promote the interaction of ERα and Src, resulting in E2 
mediated activation of Src downstream of ERK/MAPK signaling. This particular PELP1 
function has also been implicated in the development of tamoxifen resistance in transgenic mice 
[258]. HPIP, also known as pre-B cell leukemia homeobox interaction protein, is a microtubule-
binding protein that is localized predominately in the cytoplasm. HPIP interacts with ERα 
through its C-terminus and promotes the activation of PI3K and Src. E2 has been demonstrated 
to induce the formation of an ERα/PI3K/Src/HPIP complex on microtubules that activates 
AKT/MAPK pathways in breast cancer cells [259]. MTA1s is a frameshift-derived shorter 
version of MTA1. MTA1s lacks a nuclear localization signal and it sequesters ERα in the 
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cytoplasm enhancing non-genomic signaling at the expense of the genomic functions. E2 
signaling can also modulate the DNA damage response. E2 delays DNA repair by regulating 
ATR and Chk1 activation in breast cancer cells; interestingly, this is dependent on ERα mediated 





Figure 5. Targeting ER signaling in breast cancer.  There are several classes of anti-estrogens used in the clinic to 
treat ER positive breast cancer. In the absence of anti-estrogens E2 binds to ER, inducing receptor dimerization and 
nuclear translocation.  Activated ER can either interact with DNA directly or indirectly (with the aid of other DNA-
binding transcription factors) to modulate gene transcription.  Aromatase inhibitors (AIs) target the enzyme 
aromatase which is responsible for the production of E2.  Selective estrogen receptor down regulators (SERDs) 
inhibit estrogen signaling by targeting the ER for degradation. Selective estrogen receptor modulators (SERMs) bind 
to ER resulting in a conformational change that can inhibit or promote the transcription of certain estrogen regulated 




1.6 ENDOCRINE RESISTANCE IN BREAST CANCER 
 
As previously discussed, the majority of breast cancers are ER+ and rely on E2 for their 
proliferation and progression, therefore, the most effective strategy to stop or slow the growth of 
hormone-sensitive tumors is to block E2 action using endocrine therapy. Current endocrine 
therapies for ER+ breast cancer include: tamoxifen, the selective ER modulator that 
competitively inhibits E2 binding to ERα; fulvestrant, the pure anti-estrogen that induces 
receptor degradation by the proteasome; and aromatase inhibitors (such as letrozole, anastrozole 
and exemestane) which target the enzyme responsible for estrogen production. For the past few 
decades, tamoxifen (TAM) has been the most widely used drug for the treatment of breast cancer 
with success both as a long-term adjuvant therapy and as a preventative agent [261-263]. Despite 
the fact that treatment with these anti-estrogens significantly decreases breast cancer mortality, a 
large number of patients fail to respond to initial therapy (de novo resistance) or develop 
resistance after prolonged treatment (acquired resistance). Anti-estrogen resistant (also known as 
endocrine resistant) breast cancers proliferate independent of E2 signaling. Several molecules 
and signaling pathways have been proposed to explain the development of endocrine resistance, 
often with significant overlap.  
1.6.1 Growth factor signaling pathways 
Perhaps one of the most extensively studied mechanisms regarding endocrine resistance is the 
upregulation of members of the epidermal growth factor family. Approximately one third of 
breast cancers overexpress human epidermal growth factor receptor 2 (HER2), and this is 
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associated with poor prognosis and survival. Tamoxifen induces the proliferation of the 
tamoxifen-resistant cell line MCF-7/HER2-18 (which overexpresses HER2), suggesting 
crosstalk between HER2 and ERα. Furthermore, epidermal growth factor receptor (EGFR or 
HER1) and insulin-like growth factor 1 receptor (IGF1R) are also known to be upregulated in 
endocrine resistance [264, 265].  Growth factor receptor activation results in increased signaling 
of downstream PI3K/AKT and MAPK/ERK kinase cascades, resulting in increased proliferation, 
survival, growth and motility. These pathways can provide alternative means to induce 
proliferation and survival to tumors when ER signaling is inhibited.  
Overexpression of AKT has been demonstrated to confer resistance to tamoxifen and 
fulvestrant in breast cancer cells.  Moreover, TAM resistant cells have higher levels of activated 
AKT [266]. Aside from providing an alternative proliferative pathway, activation of PI3K/AKT 
and MAPK/ERK kinase cascades contributes to endocrine resistance through posttranslational 
modifications of ERα and co-regulators (discussed below). As mentioned previously, ER can 
also engage in cytoplasmic and membrane signaling complexes which can activate various 
growth factor receptors. Interestingly, hyper-activation of these pathways increases non-nuclear 
ER localization and non-genomic activity, thus creating a positive feedback loop of cross-
activation between the ER and growth factor receptor pathways.  It is important to note that both 
estrogen and tamoxifen can activate non-genomic ER activity, thereby implicating tamoxifen in 
the development of its own resistance [267, 268].  
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1.6.2 Modifications of ER and co-regulators 
One way to alter response to endocrine therapies is through modulation of ERα and its co-
repressors and co-activators. Mutation or loss of expression of ERα has been reported in a subset 
of endocrine resistant breast cancers [269, 270]. Additionally, hyper-methylation of the ERα 
promoter region results in significantly reduced expression [271]. However, loss of ERα 
expression only accounts for a small portion of endocrine resistant breast cancers.  
ERα phosphorylation has been associated with tamoxifen resistance. For example, 
phosphorylation of serine residues S118 (by MAPK), S167 and S305 (by AKT) can modulate the 
interaction of ERα with various transcriptional regulators and decrease sensitivity to tamoxifen 
in vitro [272, 273]. Thus far, only the S305 modification has been observed clinically in 
endocrine resistance [274, 275]. S305 phosphorylation alters the binding of ERα with the co-
activator SRC-1, which prevents TAM induced inactivation of the transcription complex [276].  
Phosphorylation of the methyl-transferase CARM1 by PKA allows the protein to bind to ERα 
independent of ligand, thereby preserving ERα transcriptional activity in the presence of 
tamoxifen. MED1, a subunit of the mediator co-activator complex that acts as a link between 
RNA polymerase II and transcription factors, is often overexpressed or phosphorylated in 
acquired tamoxifen resistance. Depletion of MED1 expression in cells restored sensitivity to 
tamoxifen, resulting in reduced proliferation [277].  Overexpression of the ER co-activator AIBI 
(amplified in breast cancer 1, also known as NCOA3 or SRC3) results in constitutive 
transcriptional activity of ERα, which leads to resistance to anti-estrogen treatment [278]. 
Additionally, downregulation of the co-repressor NCoR was reported in tamoxifen resistant 
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tumors.  Finally, increased levels of ER transcription factors NFκB and AP-1 have also been 
associated with endocrine resistance [279, 280].   
1.6.3 Alterations in cell cycle and apoptotic pathways 
Another category of endocrine resistance mechanisms involves the modulation of proteins 
involved in cell cycle progression and induction of apoptosis. Tamoxifen and fulvestrant reduce 
cell proliferation by inducing G1 phase-specific growth arrest. Overexpression of proteins that 
induce the progression of the cell cycle such as c-Myc, cyclin E1, and cyclin D1, contribute to 
endocrine resistance [281, 282]. Cyclin D1 promotes G1/S phase transition and is over-expressed 
in 50% of breast cancers; overexpression of cyclin D1 in cell models results in tamoxifen 
resistance. C-Myc expression can contribute to resistance by decreasing the expression of the 
negative regulators of cell cycle progression p21 and p27. Moreover, reduced expression or 
stability of p21 and p27, as well as inactivation of the RB tumor suppressor, are also reported in 
tamoxifen resistance [283, 284].  It is important to note that multiple growth factor receptors and 
their downstream signaling pathways downregulate the expression or activity of cell cycle 
regulators. HER2 overexpression reduces p27 levels, and phosphorylation of p21 and p27 by Akt 
relocates the proteins to the cytoplasm and inhibits their activity.  
Upregulation of anti-apoptotic molecules, such as Bcl2, decrease expression of pro-
apoptotic molecules, such as BIK and caspase 9, can also lead to endocrine resistance [285].  As 
before, activation of growth factor receptor signaling via the PI3K/Akt pathway is important for 
the regulation of these apoptotic/survival molecules, but additional molecules that cross-talk with 
ERα, such as NFκB, have also been implicated [279].  
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1.6.4 Other mechanisms of endocrine resistance 
Endocrine resistance can also be due to differences in drug metabolism and excretion. CYP2D6 
is a member of the cytochrome P450 family which converts tamoxifen into its active metabolites 
4-hydroxytamoxifen and endoxifen, which have 30-fold and 100-fold higher potency than 
tamoxifen respectively. Several polymorphisms of CYP2D6 alleles have been shown to reduce 
enzyme activity, resulting in a poor clinical outcome following tamoxifen treatment [286].  
Additionally, overexpression of the drug efflux transporters such as P-glycoprotein/multi-drug 
resistance protein 1 (MDR1), might influence a patient’s response to TAM by reducing overall 
drug and metabolite concentrations in the cell [287].   
 Another proposed mechanism in endocrine resistance involves the G-protein coupled 
receptor GPR30; a membrane bound receptor that mediates non-genomic estrogen signaling 
effects. Unexpectedly, both tamoxifen and fulvestrant bind to GPR30 and increase cell 
proliferation through the activation of EGFR-MAPK and cAMP signaling pathways, thereby 
enhancing estrogen signaling effects [288, 289].   
Recent studies have implicated a role for non-coding RNA in the development of 
endocrine resistance, specifically microRNA (miRNA) and long non-coding RNA (lncRNA). 
miRNAs are small strands of RNA of 18-22 base pairs in length that regulate the expression of 
target mRNAs by inhibiting translation or degrading transcripts [290]. Expression profiles of 
miRNA in breast tumor samples have been associated with pathological features such as 
hormone receptor status and proliferation index, and miRNA gene regulation has been 
implicated in breast cancer progression [291, 292].  Several miRNAs are known to be involved 
in resistance and typically target genes implicated in cell cycle/apoptosis or in growth signaling 
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pathways. Overexpression of miR-221, miR-222 and miR-206 significantly reduce ERα 
expression in MCF-7 and T47D breast cancer cells, resulting in acquired tamoxifen resistance 
[293, 294].  Furthermore miR-221/222, along with miR-15a/16,  have been shown to target genes 
involved in cell cycle inhibition (p27) and apoptosis (Bcl2) in HER2 positive breast cancers 
[295, 296]. Treatment of tamoxifen resistant MCF-7 cells with exogenous miR-15a/16 decreased 
tamoxifen-induced Bcl2 levels and re-sensitized the cells to tamoxifen toxicity [295].  Several 
miRNAs, including miR-519a, miR-301 and miR-101, all decrease PTEN expression and 
increase AKT signaling in endocrine resistant cells [297, 298].  Lastly, a recent study analyzing 
miRNA expression in matched samples from ER+ breast cancer patients treated with tamoxifen  
reported  that  high expression of miR-126 and miR-10a were associated with significantly 
longer relapse-free time after tamoxifen treatment [299].  
Long non-coding RNAs (lncRNA) are RNA transcripts between 22-200 base pairs in 
length recently implicated in breast cancer gene regulation. The lncRNA BCAR4 was found to 
be overexpressed in tamoxifen resistant ZR-75-1 cells, and has recently been shown to correlate 
with increased invasiveness and tamoxifen resistance in human tumors [300].   
 
 
1.7 NHERF1 IN BREAST CANCER 
 
Recently, studies have implicated a role for NHERF1 in the regulation of cell proliferation in 
cancer.  Overexpression of NHERF1 has been reported in breast cancer, schwannoma, and HCC 
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samples [301, 302].  Of the three, breast cancer has the most extensive analysis of the NHERF1 
expression in cancer progression [302-306]. Nevertheless, conflicting evidence has made the role 
of NHERF1 in breast cancer enigmatic.  
Interestingly, the NHERF1 gene contains several half-ERE sites in its promoter region 
and its transcription is regulated by estrogen in breast cells [162]. Furthermore, there is a 
significant correlation between NHERF1 and ER expression in human breast cancer [163]. Initial 
studies reported that overexpression of NHERF1 was significantly correlated with lower tumor 
invasiveness in breast cancer cell lines [305]. However, later studies analyzing a large number of 
breast tumor samples demonstrated the opposite, that NHERF1 overexpression is significantly 
associated with tumor stage, metastatic progression, and poor prognosis [302, 303].  
Loss of one or both NHERF1 alleles has been reported in breast and ovarian cancers. One 
study reported a relatively low number (3%) of NHERF1 gene mutations in breast cancer cell 
lines and primary tumors associated with loss of heterozygosity (LOH), yet overall loss of at 
least one NHERF1(SLC9A3R1) allele was prevalent [305]. 58% of the breast cancer cell lines 
and 22% of the primary tumor screened had deletion of at least one NHERF1 allele.  Two of the 
cell lines, MDA-MD-231 and SUM 149PT, harbored missense mutations (R180W and D301V) 
with LOH, and were subsequently shown to have reduced NHERF1 expression. The same study 
also reported a third mutation, K172N, which was found in DNA extracted from breast tumor 
tissue, but not in the adjacent normal tissue. Allelic loss of NHERF1 strongly correlated with 
tumor size and disease stage, which led the authors to postulate a tumor suppressor role for 
NHERF1 in breast cancer progression [305, 306].   
NHERF1 interacts with several proteins implicated in the initiation and progression of 
cancer.  One of the most studied is the interaction of NHERF1 with several members of the 
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PI3K/Akt pathway [307]. Loss of NHERF1 has been associated with increased Akt activation in 
MEF and breast cancer cells. NHERF1 has been shown to interact with epidermal-growth factor 
(EGFR) and platelet-derived growth factor receptors (PDGFR), as well as the phosphatase and 
tensin homolog deleted on chromosome 10 (PTEN) [308, 309].  NHERF1 interacts with the C-
terminus of EGFR and reduces its activation.  PTEN antagonizes the activity of PI3K, and it has 
been demonstrated that NHERF1 increases PTEN stability and expression.  One group reported a 
ternary complex between NHERF1, PDGFR, and PTEN, suggesting that NHERF1 may 
antagonize PDGFR signaling by promoting its association with PTEN [304, 310].  Furthermore, 
a recent study demonstrated that NHERF1 missense mutations identified in breast cancer tumors 
prevented the association of NHERF1 and PTEN.  Taken together, these studies imply that 
NHERF1’s role in cancer progression is at least in part due to its regulatory role in the PI3K/Akt 
pathway.  
Our group recently reported that NHERF1 interacts with Fz receptors and antagonizes 
Wnt/β-catenin signaling in breast cancer cells [40].  Moreover, another group reported NHERF1 
expression suppressed β-catenin signaling in mouse embryonic fibroblasts (MEF) cells.  
Interestingly, NHERF1 has also been shown to associate with β-catenin in HCC cells, where 
overexpression in the cytoplasm was observed to promote β-catenin transcriptional activity [26].  
It has been postulated that differences in NHERF1 subcellular localization can explain 
the seeming contradicting roles of NHERF1 expression in cancer. The studies showing 
overexpression of NHERF1 in breast tumors report localization of the protein in the cytoplasm of 
cancer cells, as opposed to the typical membrane localization seen in normal mammary epithelial 
cells [163, 303, 311]. The same shift in NHERF1 subcellular localization has also been reported 
in HCC cells [26].  This has led to the hypothesis that NHERF1 acts as a tumor suppressor when 
 44 
localized at the plasma membrane, but is an oncogenic protein when localized in the cytoplasm.  
One recent study has even reported nuclear expression of NHERF1 in a subset of breast tumors, 
and found that nuclear expression of NHERF1 was correlated with increased survival [304]. 
Considering the wide breadth of targets identified for NHERF1, the idea that NHERF1 function 
is highly dependent on its localization is an attractive one.  However, more information is needed 
on how NHERF1 localization is regulated under pathological conditions.  
 
1.8 RATIONALE AND AIMS 
 
Our laboratory previously identified NHERF1 as a regulator of Wnt canonical signaling, 
demonstrating a direct interaction between NHERF1 and Fz receptors [40]. Initial studies 
suggested that NHERF1 may regulate Wnt/β-catenin signaling in mammary tissue. Preliminary 
data from the laboratory also suggested NHERF1 KO mice presented a form of communicating 
hydrocephalus characterized by pattern defects in the cilia of the ependyma, a phenotype 
potentially explained by a defect in Wnt PCP signaling. Interestingly, the Wnt PCP receptor 
Vangl2 also contains a class I PDZ ligand at the C-terminus.  The observation that Vangl2 apical 
expression was lacking in NHERF1 KO ependyma led to the hypothesis that NHERF1 may 
regulate non-canonical as well as canonical Wnt signaling. Taken together, the evidence began to 
portray NHERF1 as a potential “signaling switch” between the Wnt pathways. Presumably, 
NHERF1 would regulate the signaling of these two pathways by inducing complexes that favor 
 45 
the signaling of one pathway over another (turning on PCP signaling and turning off canonical 
signaling).  
 Our group sought to determine the role of NHERF1 in the regulation of both Wnt β-
catenin signaling (specifically Wnt canonical signaling in breast cancer) and PCP signaling.  This 
thesis is comprised of the following three specific aims: 1) Determining whether NHERF1 acts 
as tumor suppressor in a Wnt-driven breast cancer model, 2) Determining the role of NHERF1 
expression and Wnt canonical signaling in endocrine resistance, and 3) Examining the role of 




Figure 6. General model.  We propose that NHERF1 acts as a molecular switch between Wnt/β-catenin and 
Wnt/PCP signaling; NHERF1 acts as a scaffold and increases the association of protein complexes that promote 
Wnt PCP signaling while simultaneously inhibiting the formation of complexes that promote Wnt/β-catenin 
activation.  
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2.0  NHERF1 AND CANONICAL WNT SIGNALING IN BREAST CANCER 
Breast cancer is the most common cancer amongst women in the United States.  Recently, 
several studies have implicated the PDZ scaffold NHERF1 in the development of breast cancer 
[301, 307].  NHERF1 overexpression decreases proliferation in several breast cancer cell models 
[306].  NHERF1 expression is upregulated by estrogen, a primary driver of breast cancer 
progression and its expression in normal mammary tissues is high.  Similarly, inhibition of 
estrogen signaling by anti-estrogens such as tamoxifen and ICI 182,780 reduces NHERF1 
expression [162, 163, 312].  Our laboratory recently identified NHERF1 as a novel suppressor of 
Wnt/β-catenin signaling in the mammary epithelium [40]. We hypothesized that NHERF1 may 
suppress Wnt canonical signaling and act as a tumor suppressor in a Wnt driven background.  
Furthermore, we our model predicted that loss of NHERF1 due to inhibition of estrogen 
signaling would increase activation of Wnt canonical signaling in the breast, potentially leading 
to resistance. In this study, we sought to determine whether NHERF1 could act as a tumor 
suppressor in a Wnt-driven breast cancer model.  Furthermore, since NHERF1 is upregulated by 
estrogen, a crucial target in breast cancer therapy, we investigated the role of NHERF1 
expression and Wnt canonical signaling in estrogen-independent and endocrine resistant breast 




NHERF1, also known as Ezrin-binding protein 50 (EBP50), is a 50-kD scaffolding protein found 
abundantly in mammary epithelium. NHERF1 is characterized by two tandem N-terminal PDZ 
domains and a C-terminal Ezrin binding domain (EBD) that attaches NHERF1 to the 
cytoskeleton. NHERF1 interacts with several proteins including ion transporters, G-protein 
coupled receptors, receptor tyrosine kinases and other cellular components  [24]. NHERF1 has 
recently been suggested to play a role as a tumor suppressor in breast cancer [302, 313, 314].     
NHERF1 mutations occur in 3% of breast cancer cell lines and primary tumors, and loss of 
heterozygosity (LOH) at the NHERF1 locus in 50% of breast primary tumors [305].  
Furthermore, NHERF1 mutations and LOH are associated with aggressive features of breast 
tumors, including tumor size, grade and stage.  Knockdown of NHERF1 has been shown to 
increase cell proliferation in multiple breast cancer cell lines, while overexpression of NHERF1 
was shown to induce apoptosis and inhibit cell proliferation [306].  Three naturally occurring 
NHERF1 breast cancer mutations have been reported: K172N, R180W, and D301V; these 
mutations are associated with larger tumor size, grade and more advanced disease state [305].   
The majority of the studies that have investigated the mechanisms by which NHERF1 
may regulate breast cancer progression have looked at NHERF1’s role in PI3K/AKT signaling. 
NHERF1 interact with PTEN and increases it expression, thereby antagonizing PI3K activity and 
significantly reducing AKT activation.  However, previous reports from our laboratory suggest 
that NHERF1 may also play a role in regulating another major proliferative pathway:  the Wnt/β-
catenin signaling pathway [40]. NHERF1 binds to Fz receptors, and its expression decreased β-
catenin signaling in breast cancer cells [40]. More recently, others have reported increased 
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nuclear β-catenin accompanied by downregulated NHERF1 expression in polycystic kidney 
disease [315].  
The oncogenic potential of Wnt/β-catenin signaling was first realized after the discovery 
that deregulation of the pathway by the mouse mammary tumor virus lead to mammary tissue 
transformation and hyper-proliferation. Mutations in Wnt signaling pathway components are 
rarely found in human breast cancer tumors,  yet studies indicate that  60% of breast cancers 
have increased activity of β-catenin signaling [157, 159]. We have shown that NHERF1 
regulates canonical Wnt signaling via direct interactions with a subset of Frizzled (Fz) receptors, 
the primary targets of Wnt, and that NHERF1 expression maintains low levels of β-catenin 
activity.  Integrity of the NHERF1 PDZ2 domain is necessary for interaction with Fz receptors; 
two of the NHERF1 breast cancer mutations, K172N and R180W are located in the PDZ2 
domain.   
The role of NHERF1 expression in breast cells is further complicated by the fact that 
NHERF1 expression is upregulated by estrogen in breast cells. Most breast tumors express 
estrogen receptor (ER) and are driven by estrogen signaling [316].  Inhibiting ER signaling by 
either antagonizing the ER or depriving the tumor of estrogen (endocrine therapy) has been a 
focus of breast cancer treatment for many decades. There are three major classes of anti-
estrogens used in the clinic:  selective estrogen receptor modulators (SERMs), selective estrogen 
receptor down-regulators (SERDs), and aromatase inhibitors (AI) [317].  The most significant 
drawback of these therapies is the development of resistance. About 30% of the women 
receiving endocrine therapy develop recurrent tumors within 15 years [318]. The identification 
of specific signaling pathways activated in recurrent tumors is essential for the development of 
novel targeted therapeutic strategies.  
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Expression of NHERF1 in breast cancer cells is highly sensitive to changes in estrogen 
signaling. Treatment with estradiol increases NHERF1 mRNA and protein levels in estrogen 
responsive breast cancer cells. Conversely, SERMS that antagonize estrogen signaling decrease 
NHERF1 expression [162]. This, along with the observation that NHERF1 expression decreases 
β-catenin signaling in breast cancer cells in culture, leads to the hypothesis that loss of NHERF1 
in breast cells following endocrine therapy could lead to increased Wnt/β-catenin signaling and 
acquired endocrine resistance.   
To investigate the role of NHERF1 in Wnt signaling and breast cancer we proposed two 
specific aims: to determine whether NHERF1 acts as tumor suppressor in a Wnt-driven breast 
cancer model, and to examine role of NHERF1 expression and Wnt canonical signaling in 
endocrine resistance. We first attempted to transform the immortalized cell line MCF10A, which 
do not express NHERF1 endogenously, with ectopic expression of WNT1A and WNT3A 
ligands. Early experiments indicated that overexpression of Wnt ligands was not sufficient for 
transformation.   
We then turned out attention to studying the role of NHERF1 expression and Wnt 
signaling in endocrine resistance. We tested the effects of the β-catenin inhibitor ICG-001 in 
estrogen-dependent and estrogen-independent breast cancer cell lines. Furthermore, we assessed 
the expression of NHERF1 and active β-catenin in primary and recurrent human breast tumors 
using immunohistochemistry (IHC) techniques. Results demonstrated that NHERF1 expression 
and endocrine resistance were not good predictors of ICG-001 sensitivity. Moreover, IHC results 
showed both positive and negative correlations between NHERF1 and active β-catenin 





Figure 7. NHERF1’s role in breast cancer.  There are two main parts to our hypothesis:  1) In ER positive breast 
cancer, estrogen maintains relatively high levels of NHERF1 expression. In these cells, NHERF1 expression 
prevents Wnt induced proliferation and β-catenin activation.  2) In endocrine resistant breast cancer, NHERF1 
function is abolished either through genetic mutation, epigenetic silencing, or inhibition of ER induced NHERF1 
expression through pharmacologic intervention (SERMs, SERDs, and A.Is).  This leads to deregulated Wnt 
signaling and cancer progression 
 
2.2 MATERIALS AND METHODS 
Reagents: All reagents were purchased from Sigma unless otherwise noted.  
Cell culture and generation of cell lines: All cell lines were cultured at 37 degrees C with 
5% CO2. MCF10A cells were purchased from ATCC and cultured in MEBM supplemented with 
10% horse serum, 1% Pen/Strep and 100 ng/mL cholera toxin.  Stable Wnt producing cell lines 
were generated by transfecting with Wnt1a and Wnt3a plasmids and selecting with increasing 
concentrations of the mammalian selection agent G418 (100-400 μg/mL) over the course of 
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several months. Two different MCF-7 parental cell lines were used during the course of this 
study, one low passage cell line from ATCC (under 50 passages) and one high passage (over 150 
passages).  Both MCF-7 parental cell lines were cultured with DMEM high glucose media 
supplemented with 10% fetal bovine serum (FBS) and 1% Pen/Strep.  T47Ds, another cell 
culture model for luminal breast cancer, was also used and cultured in RPMI high glucose media 
supplemented with 10% FBS and 1% Pen/strep.  We used 3 different estrogen-independent cell 
lines derived from MCF-7s:  MCF-7 LY2s, MCF-7 TamR and MCF-7 LTED, and two estrogen-
independent cell lines derived from T47Ds named T47D LTED and T47D TamR.   All T47D 
cell lines were provided by the Dr. Oesterreich laboratory at the Magee’s Women’s Research 
Institute. MCF-7 LTEDs were graciously provided by the laboratory of Dr. Richard Stanten at 
the University of Virginia, School of Medicine. MCF-7 TamR cells were sourced from the 
laboratory of Dr. Guoyong Wang at Tulane University School of Medicine.  All estrogen-
independent cell lines were cultured in phenol red free DMEM supplemented with 10% charcoal 
stripped FBS and 1% Pen/Strep (herby  referred to as E2-free media). 300 nM 4-hydroxy-
tamoxifen was added to the media of all TamR and LY2 cell lines to maintain SERM resistance 
phenotype.  
Adhesion-dependent growth assays:  MCF10A control and MCF10A Wnt3a and Wnt1a 
stably transfected cells were seeded onto 12 well plates at a density of 20,000 cells/well.  Total 
cell number per well was assessed using an Invitrogen automated Cell Countess at days 2, 4 and 
6 post plating.    
Soft agar colony formation assays: Anchorage independent growth of MCF10A ctrl, 
WNT1A and WNT3A cell lines was tested using soft agar colony assays in 6 well plates.  2X 
MCF10A cell culture media and agarose were mixed under sterile conditions to final 
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concentrations of 0.7% agarose for the base layer, and top layer of 0.35% agarose. Cells were 
seeded at a density of 30,000 cells/well and fed with fresh medium twice a week. Parallel 
experiments with MCF-7 cells were used as a positive control. After 4 weeks, wells were stained 
for one hour at room temperature in a solution of 0.01% crystal violet and 10% ethanol to detect 
colonies.  
NHERF1 Expression in SERM treated cells:  MCF-7 parental (high passage) cells were 
plated on 10 cm plates and rinsed a minimum of 3 times over 24 hours with E2-free media to 
remove excess estrogen.  After 24 hours, cell were seeded onto 6 well plates and treated with E2-
free media supplemented with 1 nM E2.  Once cells attached, they were treated with either 
vehicle control, 5-15 µM Raloxifene or 5-15 µM toremifene.  After 72 hours, cells were 
harvested using 300 microliters of RIPA lysis buffer (50 mM Tris-Hcl, 1% NP-40, 0.5% sodium 
deoxycholate and 0.1% SDS) per well and incubated on ice for 20 minutes.  Lysate protein 
concentration was determined using Pierce BCA protein assay. Samples were diluted 1:1 with 
2X laemli sample buffer and incubated at 100°C for 5 minutes.  30ug of lysate were loaded onto 
gels and transferred onto PVDF membranes.   Blots were blocked for 1 hour at room temperature 
using 5% skim milk in PBST (Phosphate buffered Saline with 0.1% Tween).  After blocking, 
blots were incubated overnight in blocking buffer supplemented with one of the following 
primary antibodies at 4°C: 1:500 NHERF1 (Santa Cruz), 1:300 cyclin D1 (Santa Cruz), and 
1:10000 α-tubulin (Abcam).   
BrdU proliferation assays:  MCF-7 parental (high passage) cells were seeded onto 25 
mM coverslips at low density in E2 free media with either vehicle control (0.1% Ethanol) or 1 
nM E2.  Cells cultured without estrogen were rinsed 2-4 times daily for 48 hours.  After 48 
hours, cells were treated with fresh media with a final concentration of 50% of either L cell 
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control (a murine fibroblast cell line) or Wnt3a conditioned medium (from an L cell line that 
constitutively expresses and secretes Wnt3a), with either 1 nM E2 or vehicle control.  24 hours 
after treatment with L Cell or Wnt3a medium, 0.03 mg/mL BrdU was added and cells were 
incubated for another 2 hours at 37°C.  After BrdU incorporation, coverslips were fixed with 
cold 70% Ethanol for 5 minutes and subsequently rinsed thoroughly with PBS.  Coverslips were 
incubated in 1.5 M HCl for 30 minutes at room temperature and then rinsed with PBS before 
blocking for one hour with blocking buffer (1% BSA and 5% goat serum in PBS).  After the 
cells had been blocked, 100 µl of 1:1000 BrdU antibody (Millipore) in blocking buffer was 
added to each coverslip and incubated at 4°C overnight in a humidified chamber.  Following 
incubation with primary antibody, coverslips were rinsed with PBS and treated with 1:1000 goat 
anti-mouse Alexa Fluor 546 (Life Technologies) in blocking buffer for one hour at room 
temperature. Coverslips were rinsed with PBS and incubated with 1ug/mL DAPI (Roche 
diagnostics) in PBS for 10-20 seconds, rinsed thoroughly with PBS and mounted onto slides 
using Flurogel mounting media.  For analysis, images of a minimum of 10 random fields were 
collected using confocal microscopy and percent BrdU positive cells were calculated using 
Image J.  
Wnt Rescue of SERM toxicity:  High passage MCF-7 parental cells were cultured in E2 
free media for 24 hours and rinsed 3-5 times to remove excess estrogen.  After 24 hours, cell 
were plated on 96 well plates at 3,000 cells per well in E free media (plated at 100 µl per well).  
Cells were allowed to attach for 16-24 hours and 100 µl of either L cell control or L cell Wnt3a 
conditioned media containing 2X concentrations of E2 and various concentrations of raloxifene 
or toremifene was added to each well for a total of 8 different SERM concentrations including 
vehicle control (1:1000 DMSO).  Final concentration was 100 pM E2 for all wells and 100 nM-
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30 µM of either raloxifene or toremifene with a minimum of 4 replicates per concentration.  
Total DNA was measured 4 days post treatment with SERMS using a CyQuant assay system 
(ThermoFisher Scientific C35006). After 4 days, all media was removed and cells were 
incubated at 37°C for one hour with 100 µl/well of CyQuant DNA dye. Fluorescence was 
measured using a Wallace Victor plate reader under manufacture’s Fluorescein settings (485 
ex/535 emission for 0.1 seconds).   
ICG-001 proliferation assays:  ICG-001 was purchased from Tocris Bioscience (Cat. 
No.4505). For ICG-001 proliferation assays, cells were plated on 96 well plates at approximately 
3000 cells/well (in 100 µl).  24 hours after plating, cells were treated with vehicle control (0.1% 
DMSO) or ICG-001 to a final concentration ranging from 30 nM- 30 µM.  Total DNA was 
measured using the CyQuant assay (as mentioned above) 4 days post treatment with ICG-001.  
In these experiments, parental cells were plated in regular growth medium regular estrogen-
containing FBS, and in some experiments as an extra control media was supplemented with 10 
nM E2 for all wells to test ICG-001 toxicity in the presence of excess estrogen.  All estrogen-
independent cell lines were plated in E2 free media with 300 nM 4-hydroxy-tamoxifen when 
appropriate.  
TOP-Flash only assays:  TOP-Flash luciferase reporter plasmids were purchased from 
Addgene. Cells were seeded on 6 well plates in their respective media and transfected with 
2ug/well of TOP-Flash luciferase reporter constructs using Fugene 6 transfection reagent at a 3:1 
ratio according to manufacture instructions. 8 hours post-transfection, 5-20 µM ICG-001 or 
vehicle control was added to well and cells were incubated at 37°C for 24 hours.  After 24 hours, 
cells were lysed with Promega Passive Lysis Buffer and incubated at room temperature for 15 
minutes.  Protein concentration was determined using Pierce BCA protein assay.  Luciferase 
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activity was measured by adding 100 µl of Promega Luciferase Assay Reagent (LAR) to 20 µl of 
each sample and reading immediately on a manual luminometer.  Total luminescence was 
normalized to protein concentration for each sample.  
TOP-Flash and Renilla Luciferase assays:  Renilla luciferase plasmids were graciously 
provided by the laboratory of Dr. Monga at the University of Pittsburgh, Department of 
Pathology. For TOP-Renilla luciferase assays, cells were seeded onto 6 cm plates and transfected 
with 5 µg of DNA per plate (3 µg of TOP-Flash reporter and 2 µg of Renilla reporter plasmids) 
using Xtreme-gene HP transfection reagent (Roche) at a 3:1 ratio according to manufacture 
instructions.  Cells were incubated at 37°C for 24 hours post transfection and then lysed with 300 
µl of Promega Passive Lysis Buffer per plate and scraped off of plates using a plastic spatula and 
sonicated for 5 minutes (10 second pulses at 4°C).  TOP-Flash luciferase activity was measured 
by adding 100 µL of Promega Luciferase Assay Reagent to 20 µl of cell lysate.  Immediately 
after TOP-Flash reading was collected, 100 µl of Promega Stop&Glo buffer was added to each 
sample to stop TOP-Flash reporter activity and initiate Renilla luciferase activity. Both 
measurements were done on a Wallace Victor plate reader.  
TUNEL assays:  MCF-7 parental and estrogen-independent cells were seeded onto poly-
D-lysine coated 22 mm coverslips in 6 well plates and allowed 16-24 hours to attach.  Cells were 
treated with 20 µM ICG-001 or vehicle control for 48 hours.  For a positive control, parental 
MCF-7s were treated with 20 µM raloxifene in parallel. After incubation with ICG-001 or 
raloxifene, cells were fixed with 4% paraformaldehyde on ice for 20 minutes and then rinsed 
three times with PBS.   Cells were then permeabilized with 0.2% Triton X-100 PBS solution and 
rinsed with PBS.  The coverslips were covered with 100 µl of Promega TUNEL Equilibration 
buffer and incubated at room temperature for 15 minutes. After equilibration, coverslips were 
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covered with 50 µl of rTdT buffer and incubated at 37°C for 1 hour in a humidified chamber.   
To terminate the nucleotide incorporation reaction, coverslips were incubated in 2X SCC buffer 
for 15 minutes at room temperature. Afterwards, coverslips were rinsed with PBS and nuclei 
were counterstained by immersing the slides in 1 µg/mL DAPI PBS solution for 10-30 seconds.  
Cells were then rinsed three times with PBS; coverslips were mounted onto glass microscope 
slides using Flurogel mounting media. Samples were analyzed on an Olympus Fluoview 
confocal microscope.   
Immunohistochemistry: Paraffin embedded human breast tissue samples from primary 
and recurrent tumors were acquired from the Health Sciences Tissue Bank at the University of 
Pittsburgh. Tissue sections were de-paraffinized by incubating slides in fresh xylene twice for 10 
minutes each time. Slides were washed twice with 100% ethanol for 3 minutes.  Samples were 
then rehydrated by sequentially immersing slides through graded ethanol washes (100%, 95%, 
70%, and 50%) for 3 minutes each. Following rehydration, slides were rinsed with deionized 
water and then PBS for 5 minutes.  To perform antigen retrieval, samples were placed in boiling 
citrate buffer (10 mM citric acid, 0.05% Tween, pH 6.0) and incubated in an 80°C water bath for 
one hour.  Tissue samples were then blocked with blocking buffer (5% goat serum and 1% BSA 
in PBS) for 1 hour at room temperature.  After blocking, samples were covered with blocking 
buffer containing 1:150 NHERF1 (Pierce antibodies) and 1:300 Active β-catenin (Millipore) 
antibodies and incubated at 4° C overnight in a humidified chamber.  Slides were then 
thoroughly rinsed with PBS and incubated at room temperature for 1 hour in blocking buffer 
containing 1:1000 dilutions of both goat anti-rabbit Alexa fluor 555 (Life Technologies) and goat 
anti-mouse Alexa fluor 488 (Life Technologies).  Samples were then incubated in 1µg/mL DAPI 
(Roche) for 15 minutes and then thoroughly rinsed with PBS before mounting with Flurogel 
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mounting media.  Slides were imaged on an Olympus Fluoview confocal microscope.  To 
determine relative protein expression, laser and microscope settings were kept the same for each 
matched pair set and relative fluorescence was quantified using Image J software.  
β-Catenin Western blots:  For detection of β-catenin, cell lysates from TOP-Renilla 
assays (collected in Promega passive lysis buffer) were used.  20 µg of cell lysates were loaded 
onto Tris-HCl 7.5% gels (BioRad) and separated using SDS-PAGE electrophoresis.  Gels were 
transferred onto a PVDF membrane and blocked for 1 hour at room temperature in blocking 
buffer (5% BSA in TBST).  Blots were then incubated at 4°C overnight in blocking buffer 
containing one of the following primary antibodies: 1:3000 Total β-catenin (Millipore), 1:1000 
S675 phospho-β-catenin (Cell signaling), 1:1000 S552 β-catenin (Cells signaling), 1:1000 Y654 
β-catenin (Abcam), 1:1500 Active β-catenin (Millipore),  and 1:10000 α-tubulin (Abcam).  After 
incubation with primary antibody, blots were rinsed with TBST (3 times, ten minutes each rinse) 
and incubated  for 1 hour at room temperature in blocking buffer with either 1:5000 goat anti-
mouse or goat anti-rabbit HRP conjugated secondary antibodies (BioRad and #1721011 and 
#1706515 respectively). Blots were developed using Pierce ECL substrate according to 










Table 1. Antibodies used in chapter 2 
Antibody Type Species Source  
active-β-catenin primary Mouse Millipore 05-665 
anti-rabbit Alexa 555 secondary Goat Life Technologies A-21428 
anti-mouse Alexa 488 secondary Goat Life Technologies A-11001 
anti-mouse Alexa 546 secondary Goat Life Technologies A-11030 
anti-mouse HRP secondary Goat BioRad 1721011 
anti-rabbit HRP secondary Goat BioRad 1706515 
alpha-tubulin primary Rabbit Abcam ab4074 
β-catenin primary Rabbit Millipore 06-734 
BrdU primary Mouse Millipore 05-633 
cyclin D1 primary Mouse Santa Cruz DCS-6 sc-20044 
NHERF1 primary Rabbit Santa Cruz H-100 sc-134485 
NHERF1 primary Rabbit Pierce antibodies PA5-17044 
S552 β-catenin primary Rabbit Cell Signaling 9566 
S675 β-catenin primary Rabbit Cell signaling 4176 
Y654 β-catenin primary Rabbit Abcam ab59430 
Wnt-1 primary Rabbit Santa Cruz H-89 sc-5630 
Wnt-3a primary  Mouse Santa Cruz 3A6  sc-136163 
 
Table 2. Plasmids used in chapter 2 
Plasmid Vector Source 
TOP-Flash  pTA-Luc Addgene 
Renilla-Flash  pTA-Luc Provided by S. Monga laboratory  
Wnt-1 pcDNA3 Addgene 






2.3.1 Ectopic expression of Wnt ligands in MCF10As does not induce transformation.  
To determine if NHERF1 could act as a tumor suppressor in a Wnt driven background, we first 
wanted to see if ectopic expression of Wnt ligands could transform a breast cancer cell line that 
did not express NHERF1 endogenously.  For this purpose, we chose MCF10A cells, a non-
tumorigenic mammary epithelial cell line often used in oncogenesis experiments that does not 
express NHERF1 [319]. We created two Wnt ligand producing stable cell lines derived thereof: 
MCF10A Wnt1a and MCF10A Wnt3a.   
Preliminary data suggested that ectopic expression of Wnt ligands did not significantly 
increase in anchorage dependent proliferation.  However, MCF10A Wnt3a and MCF10A Wnt1A 
cells failed to form colonies in soft agar assays (data not shown), a result confirmed by reports 





Figure 8. Wnt ligand overexpression in MCF10As. A) MCF10A were transfected with WNT1A and WNT3A 
genes and selected with increasing concentrations of G418 (final concentration 400 µg/mL) over several weeks.  
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Colonies were selected and expanded before testing for Wnt ligand expression using Western blotting techniques. 
Lane 1: MCF10As transfected with empty vector.  Lanes 2&3: Cells derived from colonies transfected with Wnt 
ligand. B) Ectopic expression of Wnt ligands does not significantly increase the proliferation of MCF10A cells.  
MCF10A, MCF10A Wnt1a and MCF10A WNt3a cells were seeded onto 12 well plates at 20,000 cells/well and cell 
number was assessed at 2, 4 and 6 days post plating. 
 
2.3.2 Wnt3a increases proliferation in estrogen deprived MCF-7 cells 
The proposed model predicts that breast cancer cells would only be sensitive to the proliferative 
effects of Wnt ligands in the absence of estrogen.  To model ER+ breast cancer, we chose MCF-
7 cells, an ER+ luminal breast cancer cell line that is highly sensitive to the proliferative effects 
of estrogen.   To test proliferation, we measured BrdU (5-bromo-2’-deoxyuridine) incorporation 
in MCF-7 cells following treatment with Wnt3a or L cell conditioned media in the presence and 
absence of estrogen.  BrdU is a thymidine nucleotide analog that is incorporated into the nuclear 
DNA of cells in S-phase, and thus can be used to identify actively dividing cells. As 
demonstrated in Figure 9, in the presence of 1 nM E2, MCF-7s have a high number of BrdU 
positive cells which is not significantly changed by the presence of Wnt3a ligands.  However, in 
the absence of estrogen basal proliferation decreases greatly, and addition of Wnt3a conditioned 
media significantly increases BrdU+ cells from 18% to 40% (p<0.01). This suggests that in 
estrogen responsive cells, estrogen is the primary driver of proliferation and the presence of Wnt 
ligands is redundant.  However, when estrogen is absent, Wnt is able to significantly increase the 




Figure 9. Parental MCF-7s only respond to Wnt in the absence of estrogen.  MCF-7s were incubated in either 
control (L cell media) or Wnt3a conditioned media for 24 hours and cell proliferation was measured using BrdU 
nucleotide incorporation assay. In the presence of estradiol, Wnt3a does not significantly increase BrdU positive 
cells.  However, following acute estrogen deprivation, Wnt3a is able to significantly increase the number or 
proliferative cells. N=3. *p<0.01 
 
2.3.3 Wnt3a rescues cells from raloxifene but not toremifene toxicity 
Previous studies have demonstrated that NHERF1 expression is regulated by estrogen in breast 
cancer cells. Tamoxifen and fulvestrant have both been demonstrated to decrease NHERF1 
expression [315].  If our hypothesis that loss of NHERF1 contributes to a Wnt-driven endocrine 
resistant phenotype is correct, then identifying a SERM which does not decrease NHERF1 
expression could prove to be clinically relevant. To this end, I tested the effects of treatment with 
raloxifene and toremifene on NHERF1 expression in parental MCF-7s. Western blot analysis 
revealed a significant decrease in NHERF1 expression after 72 hours in cells treated with 
raloxifene, but not toremifene (Fig. 10A-B). The expression of cyclin D1, a protein whose 
expression is heavily regulated by estrogen in MCF-7 cells, was used as a control for estrogen 
signaling inhibition (Fig. 10C). Interestingly, high concentrations of toremifene have been 
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clinically shown to be effective towards a subset of tamoxifen resistant patients, suggesting that 
differences between these SERMs may be relevant for acquired endocrine resistance [321].   
If loss of NHERF1 expression in breast cancer cells is indeed responsible for increased 
sensitivity to Wnt ligands, then one would expect Wnt ligands to rescue cells from raloxifene but 
not toremifene toxicity.  To test this hypothesis, MCF-7 parental cells were treated with various 
concentrations of either raloxifene or toremifene in the presence and absence of Wnt3a ligands.  
Results show that while Wnt3a conditioned media significantly increases the IC50 of raloxifene 
(4.7 µM vs 17 µM), it does not significantly change the toxicity of toremifene (Fig. 10 D-E). 
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Figure 10. Wnt3a rescues cells from raloxifene but not toremifene toxicity: TOP: MCF-7 parental cells were 
treated with either vehicle control, raloxifene (1-10 μM) or toremifene (1-10 μM) in media supplemented with 1 nM 
E2.  After 72 hours, NHERF1, alpha-tubulin and cyclin D1 expression were determined using Western blotting 
techniques and quantified using Image J. All data represents a minimum n of 3. A) Quantification of NHERF1 
shows a significant and concentration dependent decrease in raloxifene treated cells. B) Toremifene does not 
significantly decrease NHERF1 expression after 72 hours. C) Representative Western blot demonstrating reduction 
of estrogen-induced cyclin D1 expression, but not NHERF1 expression, in toremifene treated cells.  *p<0.01 
ANOVA statistical analysis. BOTTOM: MCF-7 parental cells were seeded onto 96 well plates at treated with 
vehicle ctrl, or 0.1-30 μM of SERMs in the presence of 100 pM E2. Cells were also supplemented with either 50% L 
cell (control) or Wnt3a conditioned media.  After 4 days, total DNA was measured using CyQuant proliferation 
assays. Results indicated that Wnt3a rescued cells from raloxifene growth arrest (D), but not toremifene (E).  
Results represent an n of three for each experiment.  
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2.3.4 ICG-001 inhibits the proliferation in several breast cancer cell lines 
To test the hypothesis that NHERF1 expression and Wnt canonical signaling play a role in the 
development of endocrine resistance, we investigated the effects of Wnt/β-catenin signaling 
inhibition in endocrine sensitive and endocrine resistant breast cancer cell lines. To model 
estrogen driven breast cancer, we used the MCF-7 cells mentioned previously (referred to as 
MCF-7 parental cells). Three separate estrogen-independent cell lines derived thereof were used 
to model endocrine resistant breast cancer: MCF-7 long term estrogen deprived (LTEDs), MCF-
7 tamoxifen resistant (TamR) and MCF-7 LY2s.  MCF-7 LTED, as the name would suggest, are 
an MCF-7 derived cell line that had been cultured in estrogen free media for over a year.  MCF-7 
TamRs were derived by culturing cells in increasing dosages of 4-hydroxy-tamoxifen (up to 100 
nM), while MCF-7 LY2s were originally cultured with increasing concentrations of the 
raloxifene analog LY 117018 (up to 1 µM).    
To determine whether Wnt/ β-catenin signaling was necessary for the proliferation and 
survival of MCF-7 parental and derived cell lines, cells were seeded onto 96 well plates and 
treated with either vehicle control or various concentrations of ICG-001 (0.1-30 µM). ICG-001 
inhibits the association of CBP and β-catenin in the nucleus, thus preventing β-catenin mediated 
transcription. Four days after treatment with ICG-001, total DNA was measured using a 
CyQuant proliferation assay. Results showed that ICG-001 significantly inhibited the 
proliferation of MCF-7 LTED, TamRs and LY2 cells, but not the proliferation of the parental 
cell line (Fig. 11A).  Additionally, ICG-001 inhibits the TOP-flash reporter activity of the 
estrogen-independent cell lines but not the parental (high passage) MCF-7s (Fig. 11B). These 
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results suggest that β-catenin signaling may play a major role in the proliferation of breast cancer 
cells in the absence of estrogen signaling.  
We speculated that inhibition of β-catenin signaling with ICG-001 could potentially 
increases apoptosis in the estrogen-independent cell lines. TUNEL assay techniques were used to 
measure apoptosis in MCF-7 TamR and LTED cells treated with ICG-001 or vehicle control. 
Results indicated that ICG-001 did not significantly increase the number of apoptotic cells after 




Figure 11. ICG-001 inhibits the proliferation of several endocrine resistant cell lines.  A) MCF-7 LTEDs, 
TamRs, LY2 and parental cell lines were treated with either vehicle control or 0.1-30 µM of ICG-001, after 4 days 
total DNA was measured using a CyQuant proliferation assay.  All samples were normalized to vehicle control.  B) 
MCF-7 parental and derived cell lines were transiently transfected with TOP-Flash luciferase constructs and treated 
with either vehicle control, 10 or 30 µM ICG-001for 24 hours. After 24 hours, luciferase activity was measured and 
normalized to total protein. Results show that acute treatment with ICG-001 causes a significant decrease in TOP-
Flash reporter activity in the MCF-7 LY2, TamR and LTED cell lines, but not in the parental estrogen-dependent 
MCF-7s.  C) Cells were seeded onto poly-D-lysine coverslips and apoptosis was assessed using TUNEL assay 
techniques.  LEFT: As a positive control for apoptosis, MCF-7 parental cells were treated with either vehicle control 
or 20µM raloxifene for 48 hours.  TUNEL results indicate a robust increase in apoptosis from 0.12% to 12.4%.  
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RIGHT: MCF-7 TamR and LTEDs were treated with vehicle control of 20µM ICG-001 for 48 hours.  In these 
samples virtually no apoptotic cells were detected (0% in control vs to 0.1% for ICG-001 treated cells). 
2.3.5 NHERF1 expression in endocrine resistance 
Unexpectedly, Western blots showed that NHERF1 expression in the estrogen-independent 
MCF-7 derived cell lines is comparable to parental cells in the presence of 1 nM E2 (Figure 12 
A). Acute deprivation of estrogen in the parental MCF-7s, however, reduced NHERF1 
expression by about 45%, consistent with the reports published from other groups (Fig 12 B).   
Although NHERF1 expression remained high in the estrogen-independent cell lines, we 
speculated that NHERF1 expression could convey an advantage to cell culture conditions that 
may not reflect the effects of chronic estrogen deprivation in vivo.  Therefore, we determined the 
expression of NHERF1 and activated β-catenin in human breast cancer tissue. Paraffin 
embedded human breast cancer samples of primary and recurrent breast tumors (after treatment 
with tamoxifen) provided by UPCI were probed for NHERF1 and hypo-phosphorylated 
“activated β-catenin”, or β-catenin that is un-phosphorylated at sites S33, S37 and T41 (the 
phosphorylation sites for the CK1 and GSK3 kinases) using immunohistochemistry (IHC) 
techniques as described above. Human breast IHC results show great variation in changes of 
NHERF1 and β-catenin expression between different matched pairs (Fig. 12C). While the sample 
size is inherently limiting (n=6), the data so far collected are inconclusive about the correlation 
between NHERF1 signaling and activated β-catenin in primary and recurrent tumors.  On the one 
hand, two of the six samples (B and C) have increased active β-catenin and decreased NHERF1 
expression in the recurring tumor as predicted by our model. One matched pair showed an 
unexpected increase in NHERF1 expression accompanied by decreased β-catenin activation (Fig. 
12C, pair D), while another showed a significant decrease in β-catenin activation and a small 
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decrease in NHERF1 expression (Fig. 12C, pair F). However, other samples show very little 
change in expression of either protein between tumor pairs (Fig. 12C).  
Figure 12. NHERF1 expression in endocrine resistance:  A) LEFT: Representative western blot of NHERF1 
expression in MCF-7 parental, LTED, TamR and LY-2 cell lines.  RIGHT: Protein expression was quantified using 
Image J software and normalized to α-tubulin loading control. Results show that MCF-7 LY2s are surprisingly the 
only cell line with significantly reduced NHERF1 expression (as determined by ANOVA statistical analysis), n=4 
*p<0.01. B) LEFT: Representative Western blot of NHERF1 expression in MCF-7 parental cells acutely deprived of
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estrogen and in cells supplemented with 1 nM E2.   C) Results of IHC staining of human primary (P) and recurrent 
(R) breast tumors. LEFT: Quantification of NHERF1. RIGHT: Quantification of “activated” β-catenin in the 
nucleus.  
2.3.6 The Effects of ICG-001 in other cell culture models    
To determine if the differences in ICG-001 sensitivity between parental and estrogen-
independent cell lines were a generalized phenomenon, we extended the ICG-001 studies to T47-
Ds, a luminal breast cancer cell line, and estrogen-independent cell lines derived thereof: T47D 
LTED and T47D TamR. Unexpectedly, ICG-001 inhibited the proliferation of T47D LTED, 
TamR and parental cell lines, despite the presence of estrogen in the parental cell lines (Fig. 
13A).  The IC50 of the parental T47Ds in the estrogen containing media, 3.4 µM, is similar to 
the IC50 of β-catenin inhibition reported in colon cancer cell lines (3 µM) [322].  These results 
suggested that the sensitivity to ICG-001 in breast cancer cell lines could be an effect that is 
independent of the presence of estrogen signaling. We tested this new hypothesis by extending 
the ICG-001 proliferation experiments to a different set of estrogen-dependent MCF-7s. These 
new MCF-7s were low passage MCF-7 cells (MCF-7 ATCC). Results showed that ICG-001 does 
inhibit the growth of MCF-7 ATCC (IC50: 4.9 µM), despite the presence of estrogen in the 
regular non-charcoal stripped media (Fig. 13 B).  Addition of excess E2 (10nM) to the media did 
increase the IC50 to approximately 17 µM, however this is similar to the IC50 of the MCF-7 
LY2s, which were culture in media without estrogen and 100 nM 4-hydroxy-tamoxifen.  
Paradoxically, preliminary data from TOP-Renilla assays show higher β-catenin signaling in the 
endocrine resistant cell lines than MCF-7 parental (ATCC),  but it is not clear whether or not this 
is due to differences in transfection efficiency between cells in regular media or charcoal stripped 





Figure 13. ICG-001 growth inhibition in endocrine sensitive cell lines. Cells were seeded onto 96 well plates at 
3000 cells/well.  24 hours after plating, wells were treated with appropriate cell culture media for each cell line 
containing either vehicle control of 0.03-30 µM ICG-001. A) Growth of T47D Parental, T47D LTED and T47D 
TamR cell lines are all inhibited by ICG-001 with IC50s of 3.4, 4.2 and 6.1 µM respectively. B) MCF-7 ATCC cells 
are also sensitive to ICG-001; an addition of 10nM E2 shifts the IC50 from 4.9 µM to 17 µM. C) Preliminary data 
from TOP-Renilla luciferase assays in MCF-7 ATCC and MCF-7 LTED, TamR and LY2 cells.  
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2.3.7 β -catenin phosphorylation in parental and estrogen-independent MCF-7 cell lines 
 If Wnt signaling is upregulated in acquired endocrine resistance, one would expect to see 
significant differences in β-catenin levels between estrogen-dependent and estrogen-independent 
cells.  To this end, we measured the basal levels of active and total β-catenin in the cell lysates of 
the estrogen-dependent and estrogen-independent cell lines using Western blotting techniques.  
Results showed no significant differences in the levels of active β-catenin between the various 
cell lines when compared to either total β-catenin or the loading control α-tubulin (Fig. 14 A-B).   
Since β-catenin can also be activated by PKA and AKT, we tested for levels of β-catenin 
phosphorylated at these sites, S552, S675 (Fig. 14 C-D).  Western blots showed no significant 





Figure 14. Western analysis of β-catenin expression in MCF-7 cell lines. Relative expression of total (A), active 
(B), S552 (C), and β-catenin S675 (D) were determined using Western blotting techniques in MCF-7 ATCC and 
MCF-7 LTED, TamR and LY2 cell lines.  ANOVA statistical analysis did not identify any significant changes in 




Several studies have implicated NHERF1 expression in breast cancer progression. Reports from 
out laboratory demonstrate that NHERF1 negatively regulates canonical Wnt signaling in the 
breast, implicating a novel mechanism for NHERF1 mediated breast cancer progression. 
However, unexpectedly, overexpression of WNT1A and WNT3A ligands in MCF10As did not 
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induce transformation.  One explanation is that MCF10As could have downregulated expression 
of crucial Wnt/β-catenin signaling components, such as Dvl, Fzd or LRP5/6 receptors.  Another 
explanation is that NHERF1 serves a redundant function in Wnt signaling that can be executed 
by other PDZ scaffold expressed in MCF10As. We next sought to determine if NHERF1 
expression could be relevant in endocrine resistance. To model estrogen driven breast cancer, we 
used the estrogen-dependent MCF-7 and T47D cell lines and estrogen-independent cell lines 
derived thereof. Overall, the experiments conducted for this aim were inconclusive; the role of 
NHERF1 in the regulation of Wnt/β-catenin signaling in the breast remains enigmatic.   
While the MCF-7 LTED, TamR and LY2s showed increased sensitivity to ICG-001 
mediated growth arrest compared to the high passage MCF-7s, there were no significant 
differences in NHERF1 expression in two of the three estrogen-independent cell lines. This 
suggests that the apparent dependence on β-catenin mediated proliferation the LTED and TamR 
cell lines is not inhibited by the expression of NHERF1.  Interestingly, Wnt conditioned media 
rescues MCF-7 cells from raloxifene but not toremifene induced growth inhibition. We identified 
toremifene as a SERM that does not significantly reduce NHERF1 expression in MCF-7s; 
nevertheless, it is possible the NHERF1 expression may not be the reason behind this 
phenomenon. As mentioned in chapter 1, SERMs can have different effects on signaling 
depending on the target tissue; SERMs cause conformational changes that influence ERα ability 
to bind to its co-activators or co-repressors, and the relative expression of these effectors 
determine the overall consequence of SERM treatment [323]. Other studies have demonstrated 
differences in tamoxifen, raloxifene and toremifene mediated changes in gene expression and 
enzyme induction [324]; it is possible that toremifene inhibits the expression of genes necessary 
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for Wnt-ligand mediated proliferation that are independent of NHERF1 expression.  Further 
evidence is needed to determine which genes may be involved. 
The  observation that acute estrogen deprivation of parental MCF-7s significantly 
decreases NHERF1 protein levels, yet chronic estrogen deprivation in derived cell lines does not, 
was unexpected and in disagreement with the proposed model.  This result suggests that 
upregulation of NHERF1 expression through non-estrogen mediated signaling pathways may 
present an advantage selected for in cells in culture.  Therefore, it is possible that decreasing 
NHERF1 levels too low causes disadvantages to cell health and function that out-weigh any 
possible advantage caused by increases in Wnt/β-catenin activity. The increase of NHERF1 
expression in certain samples of tamoxifen resistant recurrent breast cancer tumors suggests that, 
at least in some cases, NHERF1 expression can be up-regulated despite pharmacological 
inhibition of estrogen signaling. NFκB and mTOR signaling have both shown to increase 
NHERF1 expression, and upregulation of either of these signaling pathways could explain the 
unexpected high levels of NHERF1 [325, 326].  
Additionally, results indicating that ICG-001 inhibits the proliferation of parental T47Ds 
and MCF-7 ATCC cells in the presence of estrogen were unexpected. We chose MCF-7s as our 
model for ER-mediated breast cancer for their documented sensitivity to the proliferative effects 
of E2 [327-329].  Similarly, others have reported that T47Ds are estrogen sensitive [330].  If the 
growth of estrogen-dependent cells can be inhibited by ICG-001, then β-catenin-mediated 
proliferation is not a phenotype exclusive to endocrine resistance.  Indeed, evidence suggests that 
β-catenin and ERα interact genetically in Drosophila [331]. Furthermore, a recent study 
demonstrated that Wnt ligands can increase ERα expression, and that ERα and Wnt/β-catenin 
signaling act synergistically to promote the osteogenic differentiation of mesenchymal progenitor 
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cells [332].  Therefore, it is possible that in certain cell lines ERα could mediate some of its 
proliferative effects through crosstalk with β-catenin.  
Human IHC studies of primary and recurrent breast cancer samples were inconclusive: 
one third of the samples showed the predicted decrease of NHERF1 expression and increase of 
activated β-catenin, another third showed the opposite trend, and the last third showed very little 
change. The main limitation of this study was the small sample size (n=6) and inability to attain 
more samples. Statistical power analysis  (using G*Power software) indicates that, assuming up 
to 30% variation of samples, a total sample size of 20 would be necessary to achieve statistical 
significance  (Matched pair test, effect size 0.8, α=0.05, and power of 0.95) . 
The hypothesis predicted increased levels of activated β-catenin in estrogen-dependent 
cells; however, Western blotting results showed no differences in any of the forms of activated β-
catenin between estrogen-dependent and estrogen-independent cell lines. Unfortunately, there 
was a lot of variation in the protein levels between sets of samples, which greatly contributed to 
the lack of statistically significant results and confounding some of the conclusions of this study.  
This variation could be explained by the use of the Promega Passive Lysis buffer to collect the 
samples for Western blotting. The recipe of the buffer is unknown, but it is possible that the 
detergent type or amount in the buffer did not allow for full solubilization of the nuclear 
compartment, explaining the large variations in β-catenin levels between data sets. Furthermore, 
it is important to note that at the time these studies were conducted it was unknown that certain 
strains of MCF-7 cells are sensitive to ICG-001 despite the presence of estrogen.  Interestingly, 
preliminary data from TOP-Renilla luciferase assays indicate that the parental MCF-7 (low 
passage ATCC) cell used for the β-catenin Western blotting experiments have much less 
TCF/LEF signaling than their estrogen-independent counter-parts as determined by TOP-Renilla 
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experiments (Fig 13C), nevertheless ICG-001 still inhibits the proliferation of these cells even in 
media containing estrogen. Therefore, it is possible that the differences seen in basal TCF/LEF 
signaling as measured by TOP-Renilla reflect differences in transfection efficiency in estrogen-
dependent and estrogen-independent cell lines, and not differences in levels of activated β-
catenin. Finally, it is feasible that the observed effects of ICG-001 on proliferation could be 
explained by off-target effects of the drug that are independent of β-catenin signaling.  However, 
no such off-target effects have been reported for ICG-001 thus far, and more data is needed to 
determine if this is indeed a possibility.  
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3.0  THE NA+/H+ EXCHANGER REGULATORY FACTOR 1 (NHERF1) 
REGULATES WNT SIGNALING AND CILIOGENESIS IN EPENDYMAL CELLS 
Anny C Treat1, David S. Wheeler1,2, Stacey Barrick1, Yanmei Yang1, Donna B. Stolz3,  
Michael Tsang4, Peter A. Friedman1 and Guillermo Romero1 
1Department of Pharmacology & Chemical Biology, 2Medical Scientist Training Program, 3Department of Cell 
Biology, 4Department of Developmental Biology 
University of Pittsburgh School of Medicine, Pittsburgh, PA 15261 USA 
 
Multi-ciliated cells generate vectorial fluid flow in the brain and other organs. Deficiencies in the 
formation and organization of cilia result in developmental anomalies including hydrocephalus. 
Ciliary organization is linked to the Planar Cell Polarity (PCP) signaling pathway. Here we 
report that mice lacking the Na+/H+ Exchanger Regulatory Factor 1 (NHERF1, also known as 
EBP50) develop communicating hydrocephalus associated with disorganized and dysfunctional 
motile cilia in the ependyma. This defect is due to disruption of the Wnt signaling pathways in 
the absence of NHERF1. We show that NHERF1 binds the PCP core genes Frizzled (Fzd) and 
Vangl. We further show that NHERF1 promotes translocation of Vangl2 to the plasma 
membrane of cells in culture and to the apical surface of ependymal cells. Furthermore, NHERF1 
assembles a ternary complex containing Fzd4 and Vangl2. These results demonstrate that 
NHERF1 plays a critical role in the development of functional motile cilia. 
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3.1 INTRODUCTION 
Ciliopathies constitute a growing class of genetic diseases with clinical manifestations that 
include neurodevelopmental defects, central nervous system (CNS) anomalies, laterality defects, 
and congenital heart disease [333]. Ciliary dysfunction resulting from one or more mutations in 
genes that regulate the assembly or function of primary, sensory, or motile cilia is commonly 
shared as the origin of these syndromes. Hydrocephalus is frequently associated with genetic 
ciliary dysfunction as a consequence of abnormalities in the ependyma, a layer of ciliated 
polarized epithelial cells that differentiate from radial glia to form the lining of the cerebral 
ventricles [334]. Ependymal cilia beat in a coordinated fashion that promotes the circulation of 
cerebrospinal fluid (CSF). Mutations in genes involved in the assembly and structure of 
ependymal cilia affect CSF dynamics resulting in hydrocephalus [335-338]. The genetic factors 
that govern ciliary development and function in the ependyma remain poorly understood. Recent 
work links ependymal ciliogenesis to non-canonical Wnt signaling, specifically to the Planar 
Cell Polarity (PCP) pathway [198, 199]. 
 NHERF1 is a member of the PSD-95/Discs-large/Zo-1 (PDZ) family of proteins. 
NHERF1 contains two N-terminal PDZ domains and a C-terminal Ezrin/Radixin/Moesin/Merlin-
binding domain (EBD) that attaches to the cytoskeleton [48]. Hydrocephalus has been noted in 
NHERF1 knockout animals [39]. The origin of this phenotype is uncertain. We show here that 
the ependymal epithelium of NHERF1-/- mice contains dysfunctional cilia as a consequence of 
altered Wnt signaling. 
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3.2 MATERIALS AND METHODS 
Reagents and Materials: Primary antibodies for HA were purchased from Covance. Anti-Vangl2 
antibodies were from Abcam. Anti-NHERF1 antibodies were purchased from Santa Cruz. Anti-
GFP antibodies were from Clontech. All secondary antibodies were purchased from Jackson 
Immunoreagents. X-tremeGENE HP transfection reagent was purchased from Roche. Opti-
MEM and Ham’s F-12 media were purchased from Life technologies. All other reagents used 
were purchased from Sigma. HA-tagged human Fzd4 was kindly provided by Dr. T. 
Kirchhausen. HA-tagged rat Fzd1 was a generous gift from Dr. R. Habas. Vangl2 was purchased 
from Addgene and subcloned downstream of EGFP. Vangl1 and Vangl1∆PDZ were a gift from 
Dr. P. Gros. HA-Vangl2 was a gift from Dr. D. Ginty. 
 Immunoprecipitation and immunoblot: CHO-N10 cells stably expressing Fzd4 were 
transiently transfected with GFP-Vangl2 or empty vector. NHERF1 expressions was induced 
with 50 ng/ml tetracycline and after 48 h the cells were lysed with RIPA buffer supplemented 
with protease inhibitors and incubated for ice for 15 min. Lysates were incubated overnight at 
4°C with HA.11 monoclonal affinity matrix (Covance). Total lysates and immunoprecipitated 
protein were analyzed by SDS-polyacrylamide gels and transferred to Immobilon-P membranes. 
The blots were probed with the following specific antibodies: NHERF1 (Santa Cruz), GFP (Life 
technologies), and HA.11 (Covance). All primary antibodies were used at a concentration of 1 
µg/ml. 
 Live cell imaging/Vangl2 localization–CHO N10 cells were transfected with HA-Fzd1 and 
either EGFP-Vangl2 or EGFP-V521A-Vangl2. Twenty-four h post transfection cells were 
treated with vehicle or 50 ng/ml tetracycline to induce NHERF1 expression and incubated for 
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another 24-48 hr. Live cells were decorated with Covance HA.11 primary antibody for 30 min at 
room temperature, rinsed with PBS and then incubated with 2 µg/ml goat anti-mouse Alexa fluor 
546 (Life technologies) conjugated secondary antibodies for 30 min. After rinsing, the cells were 
imaged using a confocal microscope. The cross correlation of HA-Frizzled 1 and GFP-Vangl2 or 
GFP- V512A-Vangl2 was measured using Image J software. 
  Image Cross-Correlation Spectroscopy: CHO N10 cells transfected with GFP-Vangl2 
and HA-Fzd4 were treated with 50 ng/ml tetracycline to induce NHERF1. Live cells were 
incubated Alexa fluor 594-conjugated Covance HA.11 antibodies (2 µg/ml) for 30 min at room 
temperature to label Fzd4 receptors at the plasma membrane. Cells were rinsed and then imaged 
using an Olympus Fluoview1000 confocal microscope. To measure the autocorrelation and 
cross-correlation functions, the microscope was focused at the plasma membrane, and 100-200 
frames of a small area (30x30 pixels) were obtained by continuous scanning at a rate of 30 
ms/frame. The autocorrelation and cross-correlation functions of EGFP-Vangl2 and HA-Fzd4 
were calculated using an ImageJ plugin specifically written for this purpose.  
Fluorescence recovery after photobleaching (FRAP): CHO N10 cells were transfected 
with HA-Fzd4 and EGFP-Vangl2 and labeled as previously described and incubated with HA.11 
anti-HA antibodies(see [18,19]). A subset of cells from each group was incubated with 5 μg/mL 
goat anti-mouse secondary antibody for 30 min at room temperature to immobilize Fzd4 
receptors. All FRAP measurements were done focusing on the plasma membrane adjacent to the 
coverslip. Cells that expressed EGFP-Vangl2 at the plasma membrane were identified and 
circular regions of interest were selected and bleached with the 488-nm laser line using a 
Fluoview 1000 equipped with a SIM scanner. EGFP fluorescence recovery of the bleached area 
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was recorded over time. The data were fitted to a single exponential decay using GraphPad Prism 
and the immobile fraction of each group was determined.   
Immunohistochemistry: The brains of 4-10 week old animals (NHERF-/- and wild-type 
littermates) were fixed in 4% formalin for 48 h at 4°C, dehydrated, embedded in paraffin and 
sectioned into 5µm slices using a microtome. For immunohistochemistry, glass slide mounted 
slices were rehydrated by successive washes with xylene, 100% ethanol, 95% ethanol, 75% 
ethanol, and PBS. Antigen retrieval was performed by heating the slides in citrate buffer. 
Samples were blocked with 5% BSA and exposed to primary antibody (2 µg/ml) at 4°C 
overnight. Slides were probed with various primary antibodies (see table 4). The slides were 
washed and incubated with the appropriate secondary antibody (dilution 1:1000) for 2 h at room 
temperature, further stained with DAPI for 5 min, washed briefly, and covered with a coverslip. 
All tissues were examined with an Olympus Fluoview 1000 confocal microscope. 
Transmission Electron Microscopy: Brains were harvested and immersion fixed in 2.5% 
glutaraldehyde overnight at 4oC. Brains were sectioned such that ependymal epithelium was 
revealed on a surface of the tissue slice. Following fixation, tissue washed 3x in PBS then post-
fixed in aqueous 1% OsO4, 1% K3Fe(CN)6 for 1 h. Following 3 PBS washes, the tissue was 
dehydrated through a graded series of 30-100% ethanol, 100% propylene oxide then infiltrated in 
1:1 mixture of propylene oxide:Polybed 812 epoxy resin for 1 h. After several changes of 100% 
resin over 24 h, brain slices were embedded in molds, cured at 37oC overnight, followed by 
additional hardening at 65oC for two more days. Ultrathin (60 nm) sections of tissue were 
collected on copper grids, stained with 2% uranyl acetate in 50% methanol for 10 min, followed 
by 1% lead citrate for 7 min. Sections were imaged using a JEOL JEM 1210 transmission 
electron microscope at 80 kV fitted with a side-mount digital camera. 
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Scanning Electron Microscopy: Mouse tissues were processed as for TEM above, but 1-
mm thick longitudinal slices that reveal the surface epithelium were used. Tissue was processed 
up to the final 100% ethanol, then chemically dried using hexamethyldisilazane. Dried slices 
were mounted onto aluminum stubs, grounded with silver paint then sputter coated with 3.5 nm 
gold/palladium (Auto 108, Cressington, and Watford, UK). Samples were viewed in a JEOL 
JSM-6330F scanning electron microscope (Peabody, MA) at 3 kV.  Ciliary Function Assay–
Fresh mouse brains were sectioned into 1 mm slices using a hand held slicer (Zivic Instruments) 
and mounted onto a glass-bottomed chamber filled with clear MEM. To measure ciliary 
function, 2 µl of a suspension of 1 µm fluorescein-tagged beads were added to the observation 
space (the third ventricle) and the motion of the fluorescent beads was monitored using a 
microscope equipped with a 20X water immersion objective. Time courses of up to 60 sec were 
recorded and bead velocity was determined using ImageJ. For tracheal tissue, the tracheae were 
excised, cut longitudinally and mounted with the tracheal epithelium exposed. The fluorescent 
beads were added over the exposed surface and bead motion was examined as described.  
Nherf1 Gene Knockdown in Zebrafish: All zebrafish experiments were approved by the 
University of Pittsburgh Institutional Animal Care and Use Committee. Embryos were obtained 
from wildtype (AB*) through natural mating. NHERF1 (SLC9A3R1) antisense morpholinos (5’-
CCTGAGGTCGCTGGACATTTT-3’) (NHERF1-MO) were designed and synthesized by 
GeneTools, LLC (Philomath, OR). MO concentrations ranging from 1-10ng were injected into 
the 1-cell stage embryos as previously described [339]. Embryos were incubated to the desired 
stage, then directly imaged under a Leica stereomicroscope and photographed using a digital 
camera.  
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 Statistical analysis: All experiments were repeated at least three times. GraphPad PRISM 
was used for all statistical analyses 
 
Table 3. Plasmids and constructs used in Chapter 3 
Plasmid/Construct Vector Source 
EGFP-Vangl1 pCS2 P. Gros laboratory 
EGFP-Vangl1 ΔPDZ pCS2 P. Gros laboratory 
EGFP-Vangl2  pcDNA3.1+ 
G. Romero laboratory (from EGFP and Vangl2  Addgene 
vectors) 
EGFP-Vangl2 V521A pcDNA3.1+ G. Romero laboratory (site directed mutagenesis)  
HA- Fzd4 pcDNA3  T. Kirchhausen laboratory 
HA-Fzd1 pcDNA3.1+ Cloned from pCS2+ vector provided by R. Habas laboratory 
HA-Vangl2 pCS2+ D. Ginty laboratory 
NHERF1 morpholinos   GeneTools, LLC (Philomath, OR) 
 
Table 4. Antibodies used in Chapter 3  
Antibody Type Species Source  
anti-hamster Alexa 488 secondary  Goat Abcam ab173003 
anti-rabbit Alexa 594 secondary Goat Life technologies A-11012 
anti-mouse Alexa 488 secondary Goat Life technologies A-11001 
anti-mouse Alexa 546 secondary Goat Life technologies A-11030 
anti-mouse HRP secondary Goat BioRad 1721011 
anti-rabbit HRP secondary Goat BioRad 1706515 
alpha-tubulin primary Rabbit Abcam ab4074 
β-catenin primary Rabbit Millipore 06-734 
GFP primary Rabbit Life technologies A-6455 
HA.11 primary Mouse Covance 16B12 MMs-101P 
HA.11 conjugated matrix primary Mouse Covance 16B12 AFC-101P 
NHERF1 primary Rabbit Santa Cruz H-100 sc-134485 
NHERF1 primary Rabbit Pierce antibodies PA5-17044 
Mucin-1 primary Ar. Hamster ThermoFisher Sci MA5-11202 




3.3.1 NHERF1 -/- mice develop communicating hydrocephalus 
The mice used in these studies were derived from the NHERF1-/- clones developed by 
Shenolikar et al [39] after back breeding with C57BL/6 for 10 generations to produce an isogenic 
line. About 35% of the NHERF1-/- mice showed clinically relevant hydrocephalus (Fig. 15A-B) 
between 28 and 32 days after birth. Ventricular dilation was detected in all animals examined 
(n=12), independently of whether or not external signs of hydrocephaly were visible. Dilation of 
the cerebral ventricles was not found in any of the wild type and in only one of the heterozygote 
animals. Detailed examination of brain slices from severely hydrocephalic NHERF1-/- animals 
did not reveal obstructions in the ventricles, arachnoid granulations, or the cerebral aqueduct, 
suggesting that the syndrome is a form of communicating hydrocephalus. To confirm that 
NHERF1 knockdown is sufficient to cause hydrocephalus, we injected 1-cell stage zebrafish 
(Danio rerio) embryos with antisense morpholino oligonucleotides targeted to the 
nherf1/Slc9a3r1 initiation codon (NHERF1-MO). All injected embryos showed impaired balance 
and motility accompanied by severe hydrocephalus and cardiac edema at 48 h post fertilization 
(hpf) (Fig. 15C). This phenotype was accompanied by a shortened longitudinal axis and defects 




Figure 15. NHERF1-/- mice display hydrocephalus. A) Comparison of two 28-day old NHERF1+/+ (left) and 
NHERF1-/- (right) littermates. B) Nissl-stained coronal sections from NHERF1+/+ (left) and NHERF1-/- mice at 
P28. C) Depletion of nherf1 in zebrafish embryos produced pronounced hydrocephalus (arrows) and cardiac edema 
(*) 2 days post-fertilization. D) NHERF1 knockdown also resulted in tail developmental defects.  Data for sections 





3.3.2 Ciliary defects in NHERF1 -/- mice 
We examined the expression of NHERF1 in the ependyma and choroid plexus of wild-type mice. 
NHERF1 is abundantly expressed in the ependymal epithelium (Fig. 16A). Because of the high 
levels of NHERF1 in ependyma, and given that impaired ciliary function is a frequent cause of 
hydrocephalus [335-338], we stained ependymal cilia by staining with acetylated α-tubulin 
antibodies (Fig. 16B). Compared to wild type animals, the number of cilia was reduced in 
NHERF1-/- mice (Fig. 16B). Many ependymal cells had fewer cilia, and some had none. A 
similar phenomenon was observed in the otic vesicles of zebrafish embryos injected with 
NHERF1-MO (Fig. 16C). The number of cilia present in the cristae of the otic vesicles of 
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NHERF1-MO injected embryos were reduced in 38 of the 42 specimens examined (Fig. 16C). 
Importantly, NHERF1-MO injections did not disrupt the actin cap of the otic vesicle epithelium, 
suggesting that NHERF1 knockdown had no effects on the apical-basolateral polarization of the 
cells. Scanning electron microscopy studies confirmed the tubulin staining data, demonstrating a 
significant reduction in the number of cilia in NHERF1-/- mice. The images further showed 
significant differences in the orientation of the cilia, with the ciliary tufts of adjacent cells often 
pointing in opposite directions (Fig. 16D). Importantly, the absence of NHERF1 did not alter the 







Figure 16. NHERF1 expression in the ependyma. A) Immunofluorescence staining of a sagittal section of the 
third ventricle of a NHERF1+/+ mouse. CP: choroid plexus; E: ependymal layer. Sagittal sections of paraffin 
embedded P28 wild type mouse brain were stained with anti-NHERF1 antibody followed by a TRITC-labeled 
secondary antibody. The sections were then imaged using a confocal microscope. B) Ciliary defects in the NHERF1-
/- mouse. Sagittal sections of the ependyma of P28 wild type and NHERF1-/- mice were stained with antibodies 
specific for acetylated α-tubulin and NHERF1. The bar represents 10 µm. C) Ciliary defects in the otic vesicle 
caused by injection of NHERF1-MO. Whole embryos (48 hpf) were fixed in 4% PFA, stained with phalloidin and 
anti-α-tubulin and the otic vesicles were examined by confocal microscopy. D) Scanning electron micrograph of the 
ependyma of wild type and NHERF1-/- mice. E) Defective orientation of ependymal cilia in the NHERF1-/- mouse.  
Transmission electron micrographs of the surface of ependymal cells from P28 wild type and NHERF1-/- mice. F) 
Comparison of the ependymal ciliary orientation in NHERF1+/+ and NHERF1-/- mice. To measure the orientation of 
the cilia, the angles formed by the basal body of each cilium and the tangent to the cell surface (θ) were measured 
and averaged for all cilia in each field. The deviation from the average orientation was determined for each 
individual cilium as θ-θAverage.  Data for sections A & B were generated by David Wheeler, sections D-F were 







To evaluate the orientation of the ependymal cilia, we performed transmission electron 
microscopy experiments and measured the relative angles of the basal bodies of the cilia with the 
surface of the cell (Fig. 16E, 16F). This analysis demonstrated that, whereas the basal bodies of 
the wild type animals were roughly oriented in the same direction (± 5 degrees), those of the 
NHERF1-/- animals were disorganized, pointing in random directions (Fig. 16E). 
The ultrastructure of the residual cilia found in NHERF1-/- mice was unremarkable. The 
cilia displayed the typical 9+2 structure of normal motile cilia, and individual cilia were of 
approximately the same length and diameter when compared to the wild type ependyma (Fig. 
17). This suggests that NHERF1 is not structurally involved in the architecture of the cilia. Thus, 
NHERF1 ablation causes reduced number and altered orientation of the cilia but does not alter 




Figure 17. Ultrastructure of the ependymal cilia. A) Transmission electron micrographs of the motile cilia of 
NHERF1+/+ and NHERF1-/- does not reveal any differences in architecture. B-C), Scanning electron microscopy 
does not reveal any differences in length and diameter between NHERF1+/+ and NHERF1-/- ependymal cilia.  Data 





The cross-species hydrocephalus phenotype suggests defects with vital functional 
consequences. Therefore, we examined the ability of the ependymal cilia to generate 
hydrodynamic fluid movement. This was done using 1 µm fluorescein-labeled latex beads placed 
onto the third ventricle of freshly prepared brain slices from 28-day old mice (Fig. 18A). The 
fluorescent beads moved rapidly and in an elliptical trajectory in the wild type slice preparations 
(average velocity =18.2 ± 2.2 µm/s). In contrast, there was little discernable movement in the 
NHERF1-/- slices (average velocity = 1.1±1 µm/s) (Fig. 18B), which was statistically 
indistinguishable from the Brownian motion of the beads in the azide-poisoned brain slices that 
served as a negative control.  
 
 
Figure 18. The cilia of NHERF1-/- ependyma are dysfunctional. A) Ciliary function was determined by 
measuring the motion of 1 µm fluorescein-labeled beads placed within the third ventricle of sagittal brain slices 
obtained from P28 wild type and knockout mice. To illustrate the motion, 3 successive images (∆t=0.1 s) were 
colored red, green and blue, respectively, and combined in ImageJ. The image on the left, characteristic of the wild 
type brain slices, shows no superposition of the three colors, indicating rapid motion of the beads. The beads of the 
NHERF1-/- slices appear white in the montage because all three colors (red, green and blue) coincide at all times, 
indicating lack of motion. The right side panel (Azide) shows the results obtained with a wild type slice poisoned 
with azide. Refer to Supplementary Movie SM1 for complete visualization of the experiment. B) Tracking of 
individual beads in wild type (WT) and knockout (KO) mice calculated as described. The right panel shows average 
velocities estimated from the tracking of individual beads. (*) denotes statistically significant differences (p<0.001; 
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results obtained from three independent experiments).  Data for this figure was generated by David Wheeler and 
Guillermo Romero.  
 
3.3.3 NHERF1 regulates Wnt signaling 
Although these results imply that NHERF1 is required for the formation of functional cilia, 
NHERF1 is excluded from the cilium and is not essential for the formation of primary cilia 
[340], suggesting that NHERF1 does not play a structural role in cilia formation. Therefore, we 
turned our attention to the signaling pathways involved in the development of functional motile 
cilia. A well-documented regulator of motile cilia is the Planar Cell Polarity (PCP) signaling 
pathway [198, 199]. Ablation of two of the PCP core genes, Celsr/Flamingo and Van 
Gogh/Vangl, causes dysfunction of motile cilia and a hydrocephaly phenotype similar to the one 
we describe [198, 199]. Furthermore, we recently showed that NHERF1 interacts directly with 
Frizzled receptors and negatively modulates canonical Wnt signaling in breast cancer cell 
cultures and in murine breast ducts [40]. Therefore, we hypothesized that the effects of NHERF1 
ablation on ciliary development are a consequence of NHERF1’s function in Wnt and PCP 
signaling.  
 We measured nuclear β-catenin levels in brain slices of wild type and NHERF1-/- 
animals to test the role of NHERF1 in the coupling of Wnt signaling in the ependyma. β-catenin 
levels were higher in the nuclei of knockout animals (Fig. 19A). Because Vangl2 plays a crucial 
role in the development of tissue polarity and contains a typical PDZ binding motif in its C-
terminus, we examined the effects of NHERF1 ablation on the expression and subcellular 
distribution of Vangl2. In normal ependyma, Vangl2 localizes to the apical surface of the cells in 
close proximity to the cilia [341]. We found substantial co-localization of NHERF1 and Vangl at 
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the apical surface of the ependyma of wild type animals. In contrast, Vangl2 expression was 
reduced and miss-localized in the ependyma of the NHERF1-/- mice (Fig. 19B). Importantly, 
mucin-1 staining was comparable in wild type and knockout animals, suggesting that the miss-
localization of Vangl2 was not caused by defects in the apical-basolateral polarization of the 





Figure 19. Abnormal canonical and non-canonical Wnt signaling in the ependyma of NHERF1-/- mice. A) 
Increased nuclear β-catenin levels in ependyma of NHERF1-/- mice. Brain slices from NHERF1+/+ and NHERF1-/- 
mice were fixed and stained with a monoclonal antibody that recognizes the activated form of β-catenin. B) Vangl2 
mislocalization in NHERF1-/- ependyma. Slices showing the cerebral aqueduct of from NHERF1+/+ (upper panels) 
and NHERF1-/- (lower panels) were stained with specific anti-NHERF1 and anti-Vangl2 antibodies. The second row 
of nuclei is absent in the NHERF1-/- sample because of the dilation of the aqueduct as a consequence of 
hydrocephalus. C) Defective ciliogenesis is not accompanied by gross defects in the apical-basolateral polarization 
of the ependymal epithelium. Brain sections showing the third ventricles of wild-type and knockout animals were 
stained with mucin-1 and α-tubulin antibodies. Notice normal expression of mucin-1 in the ependyma of NHERF1-/- 
animals independently of the presence of cilia.   Data for section A was collected by David Wheeler.  
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3.3.4 PDZ domain-PDZ ligand interactions regulate the traffic and function of Vangl2  
To further examine the role of NHERF1 in Vangl2 traffic, we transfected CHO cells that express 
NHERF1 in a tetracycline-dependent manner (CHO-N10) with HA-tagged-Fzd1 and EGFP-tagged-
Vangl2 constructs. In the absence of tetracycline (i.e., no NHERF1), the Vangl2 construct was expressed 
primarily in cytosolic structures (Fig. 20A). Addition of tetracycline increased the plasma membrane 
levels of EGFP-Vangl2, where it co-localized with Fzd1 (Fig. 20A, 20C). We hypothesized that NHERF1 
regulates Vangl localization and traffic by direct interactions with the Vangl C-terminal PDZ binding 
motif. To test this hypothesis, we transfected CHO-N10 cells with EGFP-V521A-Vangl2, a mutant in 
which the C-terminal valine has been replaced by alanine, thus disrupting its binding to PDZ scaffolds. 
The mutant Vangl2 was retained in cytosolic vesicles, independently of the expression of NHERF1 (Fig. 
20B, 20C). Furthermore, equivalent results were obtained with Vangl1, which harbors an identical C-
terminal PDZ binding motif (Fig. 21). Therefore, an intact PDZ binding motif in Vangl1/Vangl2 is 
required for correct localization. 
 Because NHERF1 contains two PDZ domains, we investigated the effects of mutations of each 
individual PDZ motif on the distribution of Vangl2. CHO cells were transfected with EGFP-Vangl2 and 
Flag-tagged NHERF1 constructs harboring mutations in the core of one or both PDZ domains (S1: 
mutated PDZ-1: S2: mutated PDZ2; S1S2: both PDZ domains mutated). Co-transfection with wild-type 
NHERF1 promoted limited plasma membrane localization of Vangl2; in contrast, plasma membrane 
localization was not detected when any of the PDZ domain mutants were co-transfected with EGFP-
Vangl2 (Fig. 20D). Interestingly, the effects of wild type NHERF1 on the plasma membrane expression 
of EGFP-Vangl2 were much greater in cells that had been transfected with Frizzled receptors (compare 
Fig. 20A and Fig. 20D). Therefore, we hypothesized that the expression of Vangl2 at the plasma 
membrane required the formation of ternary complexes containing NHERF1, Vangl2 and Fzd. To 
confirm the formation of these complexes, we performed co-immunoprecipitation experiments in CHO-
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N10 cells transfected with HA-tagged Fzd4 and EGFP-Vangl2. We found that, as predicted, NHERF1 co-
immunoprecipitated with Fzd4 and Vangl2 (Fig. 22A, 22B). We also observed a weak interaction 
between Vangl2 and Fzd4 that was significantly enhanced by the expression of NHERF1 (Fig. 22C). 
 
 
Figure 20. NHERF1 promotes plasma membrane localization of Vangl2. A) CHO-N10 cells expressing 
NHERF1 in a tetracycline-sensitive manner were transfected with HA-Fzd1 and EGFP-Vangl2. The cells were 
treated with 50 nM tetracycline or vehicle, decorated with anti-HA antibody followed by Alexa 594-labeled 
secondary antibody, and examined by confocal microscopy.  B) Same as A except that the cells were transfected 
with an EGFP-tagged Vangl2 construct in which the C-terminal PDZ binding motif has been mutated to preclude 
binding to PDZ domains (V512A-Vangl2). C) Co-localization of HA-Fzd1 and EGFP-Vangl2. The co-localization 
was quantified using the Spearman correlation coefficient measured using ImageJ. The correlation coefficients 
shown represent the average obtained from >50 cells for each set, examined in six separate experiments. The symbol 
(*) denotes statistically significant differences (p<0.001). D) NHERF1-induced plasma membrane localization of 
Vangl2 requires both PDZ domains. CHO cells co-transfected with Flag-tagged NHERF1 constructs and EGFP-
Vangl2 were fixed, decorated with anti-Flag antibodies and examined with a confocal microscope. Only the wild 
type NHERF1 construct promoted plasma membrane localization of Vangl2. Wild-type NHERF1 co-localized with 
Vangl2; reduced co-localization was observed with the S1 and S2 mutants, whereas the S1S2 mutant did not co-





Because NHERF1 contains two PDZ domains we hypothesized that NHERF1 promotes 
the formation of Fzd4-NHERF1-Vangl2 ternary complex through its interactions with the C-
terminal PDZ binding motifs of Fzd4 (–ETVV) and Vangl2 (–ETSV). To test this hypothesis, we 
co-transfected HEK293S GnTI cells (which contain low levels of NHERF1 but express abundant 
endogenous Fzd4) with HA-tagged Vangl2 and FLAG-tagged NHERF1 constructs (wild-type, 
S1, S2 and S1S2). We subsequently immunoprecipitated HA- Vangl2 and detected the presence 
of endogenous Fzd4 in the immunoprecipitate by Western blotting. The results shown in Fig. 
22D indicate that NHERF1 requires both PDZ domains to promote the formation of Fzd4-
Vangl2 complexes. These data are consistent with the formation of NHERF1–Fzd4–Vangl2 
ternary complexes by a mechanism that involves the interactions of the C-terminal PDZ ligands 
of Vangl2 and Fzd4 with the PDZ domains of NHERF1. We further studied the formation of 
these complexes by optical methods using an N-terminal-EGFP-tagged Vangl2 construct and 
Fzd4 tagged with an HA epitope near the N-terminus such that it is exposed to the extracellular 
milieu (Fig. 23A). These cells were incubated with Alexa594-tagged anti-HA antibody 
specifically to label the HA-Fzd4 exposed to the membrane. In one set of experiments, the HA-
tagged Fzd4 was immobilized at the membrane by addition of a crosslinking secondary antibody 
and the mobility of the EGFP-Vangl2 construct was determined by FRAP. Figure 23B shows 
that the addition of the crosslinking antibody decreases the mobility of Vangl2 only in cells that 
express NHERF1. We further examined formation of ternary complexes using image cross-
correlation spectroscopy (ICCS), a technique that measures complex formation by determining 
the correlation of the intensity fluctuations of differentially labeled fluorescent components. In 
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the absence of NHERF1, the Fzd4-Vangl2 cross-correlation was negligible; in contrast, strong 
positive cross-correlation was observed after induction of NHERF1 expression (Fig. 23C). These 
results strongly support the hypothesis that NHERF1 scaffolds the formation of a complex 




Figure 21. Vangl1 requires NHERF1 to traffic to the plasma membrane. CHO-N10 cells were co-transfected 
with HA-tagged Fzd1 and EGFO-Vangl1. NHERF1 expression was induced with tetracycline. After decorating the 
cells with Alexa594-anti-HA, the cells were imaged with a confocal microscope. A) Vangl1 co-localizes with Fzd1 
at the plasma membrane only in cells that express NHERF1. B) A Vangl1 mutant in which the PDZ binding motif 









Figure 22. Fzd and Vangl2 bind NHERF1. A) CHO–N10 cells were transfected with HA-Fzd4, and the formation 
of a Fzd4-NHERF1 complex was determined by co-immunoprecipitation of the HA-tag followed by Western 
blotting with specific anti-NHERF1 antibodies. NHERF1 expression was induced by the addition of 100 ng/ml 
tetracycline. B) CHO-N10 cells were co-transfected with an EGFP-tagged Vangl2 construct and induced with either 
vehicle or 100 ng/ml tetracycline. After immunoprecipitation of NHERF1 using a specific antibody, the presence of 
the GFP label in the immunoprecipitated material was determined by Western blotting. C) CHO-N10 cells were co-
transfected with HA-Fzd4 and EGFP-Vangl2. After induction with either vehicle or 15 ng/ml tetracycline, the HA-
tagged material was immunoprecipitated, and the presence of the GFP tag in the co-immunoprecipitate was 
determined by Western blotting. D) Both PDZ domains of NHERF1 are required for the interaction of Fzd4 and 
Vangl2. Cells co-transfected with HA-Vangl2 and FLAG-tagged NHERF1 constructs (wt, S1, S2 and S1S2) were 








Figure 23. NHERF1 and Wnt receptors form a ternary complex: A) A model for the NHERF1-induced 
interaction of Fzd4 and Vangl2. We propose that Fzd4 and Vangl2 interact with the PDZ domains of NHERF1. In 
the absence of NHERF1, Fzd4 and Vangl2 interact only weakly; however, NHERF1 expression induces the 
formation of a Fzd4-Vangl2 complex. B) Addition of HA-specific and cross-linking antibodies immobilizes Vangl2 
only when NHERF1 is expressed. CHO-N10 cells transfected with HA-tagged Fzd4 and EGFP-Vangl2 were 
induced with vehicle or 100 ng/ml tetracycline. Live cells were tagged with Alexa594-labeled anti-HA antibody 
(HA.11) followed by a secondary anti-mouse IgG cross-linking antibody. The mobility of EGFP-Vangl2 was 
determined by FRAP. C) Cross-correlation analysis of the formation of Fzd4-Vangl2 complexes. CHO-N10 cells 
co-transfected with HA-tagged Fzd4 and EGFP-tagged Vangl2 were incubated with Alexa594-anti-HA antibody. 
The autocorrelation function of EGFP-Vangl2 and the cross-correlation function of the EGFP label to the Alexa594 
label were determined. The ratio of the cross-correlation (GCC) to the autocorrelation amplitudes is directly 





PDZ proteins are ubiquitous molecular scaffolds that control multiple aspects of protein traffic 
and function. These regulatory roles are accomplished by the assembly and disassembly of 
multimeric complexes containing specific signaling and structural molecules that affect the 
distribution and functional characteristics of the target proteins. NHERF1 is one of the better-
characterized members of this family. Initially identified as a regulator of the renal proximal 
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tubule brush border membrane Na+/H+ exchanger [22], NHERF1 serves a central  physiological 
role in the regulation of mineral-ion homeostasis, including the regulation of parathyroid 
hormone receptor signaling [342-344]. A global NHERF1 knockout mouse was reported in 2002, 
and hydrocephalus was noted as a secondary phenotypic characteristic [39]. Our observations 
confirm the hydrocephalus phenotype of the NHERF1-/- mouse; moreover, we demonstrate that 
NHERF1 knockdown in zebrafish embryos also causes hydrocephalus, plus additional 
phenotypic issues not previously described in the mouse. Furthermore, we report here that the 
hydrocephalus caused by ablation of NHERF1 is associated with ciliary dysfunction in the 
ependymal lining of the cerebral ventricles.  
 How does NHERF1 modulate ciliogenesis? A direct, structural role for NHERF1 in the 
assembly of the cilium itself is unlikely. NHERF1 is excluded from the cilium [340] and the 
ependymal cells of NHERF1-/- animals contain cilia. Furthermore, the ependymal cilia of the 
NHERF1-/- mice have normal 9+2 structures, and are of normal length and diameter. A similar 
form of hydrocephalus linked to defective motile cilia was recently reported in mice missing the 
PCP genes Celsr2 and Celsr3. The main defect in the motile cilia of Celsr2-/- mice is deficient 
organization of the cilia, which results in impaired hydrodynamic CSF flow [198]. This defect 
was associated with anomalous planar polarization of the distribution of Vangl2, which failed to 
localize asymmetrically on the apical surface of the ependymal cells [198]. However, the defects 
caused by NHERF1 ablation are distinct from the typical PCP core gene knockouts, which 
involve primarily cilia disorganization without loss of cilia [345]. These differences may be 
linked to the increased β-catenin signaling resulting from NHERF1 ablation. A recent study 
linked increased levels of β-catenin to high expression of histone deacetylase (HDAC), leading 
to reduced tubulin acetylation and, therefore, impaired cilia formation [346]. Thus, NHERF1 
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appears to serve as a molecular router that regulates the relative input of Fzd-mediated signals to 
the canonical β-catenin pathway or to the alternative PCP pathway. In conclusion, we propose 
that the effects of NHERF1 are a consequence of two correlated activities: 1) inhibition of 
Wnt/β-catenin signaling; and 2) recruitment of Vangl proteins to the plasma membrane to 
promote PCP signaling. This latter role of NHERF1, viz regulating traffic of target proteins to 
the plasma membrane of polarized epithelia, is consistent with previous studies [347-350].  
 The direct regulation of Wnt signaling pathways by specific PDZ proteins has been 
documented. Many of the molecular components of the Wnt signaling pathways contain 
canonical PDZ domains  or C-terminal PDZ-binding motifs, including 8 of the 10 mammalian 
Fzd receptors, β-catenin, and Vangl1/2 [91]. However, little is known about the role of these 
PDZ binding motifs and their interacting partners in the regulation of Wnt and PCP downstream 
signals. Because PDZ proteins are essentially scaffolds, the formation of multimeric complexes 
is a central feature of their role in the regulation of biological processes. Thus, the multi-PDZ 
protein MAGI-3 has been implicated in the stabilization of complexes containing Vangl2 and 
Fzd4/Fzd7 that localize to cell-cell contact sites [351]. We show here a similar scaffolding role 
for NHERF1 although with a very different subcellular distribution. NHERF1 is targeted to the 
apical end of polarized cells [91]. Inasmuch as our results demonstrate that Vangl2 is apical in 
wild type but not in NHERF1-/- ependyma, we conclude that NHERF1 is required for the apical 
localization of Vangl2. 
 The formation of Fzd-Vangl2 complexes has been postulated to play a central role in PCP 
signaling. Vangl2 interacts with Fzd3, but evidence for the interaction of Vangl2 with other 
members of the Fzd family is lacking [197]. We show here that NHERF1 promotes the 
interaction of Vangl2 with Fzd4 acting as a scaffold linking both proteins. This model provides a 
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mechanism for the regulation of PCP events by Fzd receptors that, unlike Fzd3, do not interact 
efficiently with Vangl2. Furthermore, this role of NHERF1 may not be unique. Recent reports 
suggest that other multi-PDZ proteins may also assemble protein complexes that include Fzd4 
and Vangl2 [351]. Thus, several PDZ scaffolds may play redundant roles in coupling of PCP to 
diverse downstream functions depending on their relative levels of expression in specific cells 
and tissues. Our data demonstrate that NHERF1 is a critical PDZ scaffold involved in the 
coupling of the PCP pathway to the development of functional cilia.  
 We conclude that NHERF1 plays a crucial role in the regulation of β-catenin signaling, in 
the recruitment of Vangl proteins to the apical surface of polarized cells, in the formation of 
Vangl2-Fzd complexes, and in the proper development of cilia. To determine whether or not 
other ciliated organs were affected, we examined the upper respiratory pathways of wild type 
and knockout animals. We observed reduced numbers of cilia and ciliated cells in the trachea of 
knockout animals, although the defect was less dramatic than in the ependyma. Importantly, the 
ciliary defects observed in the tracheae of the NHERF1-/- animals were accompanied by a 30% 
decrease in fluid flow (Fig. 24). We conclude, therefore, that NHERF1 plays a general role in the 
proper orientation and function of motile cilia. 
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Figure 24. NHERF1 ablation alters cilia organization and function in the respiratory tract. A) Reduced 
number of motile cilia on the surface of the respiratory epithelium of NHERF1-/- mice. B) Scanning electron 
micrographs of the tracheae of NHERF1-/- mice shows patches of cells with no cilia. C) Ciliary function was 
determined in sagittal sections of the tracheae of NHERF1+/+ and NHERF1-/- animals. Fresh sagittal sections were 
extended on a microscope slide. After addition of medium and 5µl of a suspension of fluorescent beads, a coverslip 
was placed on top of the sections and the movement of the beads was recorded by fluorescence microscopy using a 
20X objective at 1-second intervals. The figure shows the relative positions of the beads using a color code (blue: 
time=0, green: time=1 second, red: time-=2 seconds). D) The average velocity of the microbeads was determined as 
described in C. * denotes statistical significance (p<0.001, N=3 independent experiments; at least 15 beads per 




4.0  THESIS SUMMARY AND DISCUSSION 
The focus of this thesis has been determining the role of the PDZ scaffold NHERF1 in the 
regulation of Wnt signaling in the ependyma and mammary tissues; more specifically Planar Cell 
Polarity and ciliogenesis in the ependyma and Wnt/β-catenin signaling in breast cancer.  
Although several studies have implicated NHERF1 in the breast cancer progression, until 
now all of these studies have focused on NHERF1’s regulation of PI3K/AKT signaling in the 
breast [307].  Recently, our laboratory reported that NHERF1 expression reduced β-catenin 
activity in breast cancer cells [40]. Based on the results of this earlier study, our group sought to 
determine the role of NHERF1 and Wnt signaling in mammary oncogenesis and progression.  
However, the results of the studies in chapter 2 were overall inconclusive.  For one, MCF10As, 
which do not express NHERF1, could not be transformed through the expression of Wnt ligands, 
a result confirmed independently by a separate group [320].  It’s possible the MCF10As have 
downregulated expression of the mammalian homologs of porcupine and wntless, resulting in 
improper Wnt ligand production and secretion. Unfortunately, we were not able to test if the Wnt 
transfected MCF10As were able to secrete the transfected ligands. MCF10As could also 
potentially have decreased Fzd or LRP5/6 expression.  
Although we could not effectively test how NHERF1 expression effects Wnt-mediated 
transformation, we sought to determine if NHERF1 expression could contribute to endocrine 
resistance in breast cancer cells. As mentioned in previous sections, E2 expression stimulates 
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NHERF1 expression in breast cells and certain anti-estrogens such as tamoxifen and fulvestrant 
decrease NHERF1 expression in breast cancer cell lines.  Therefore, we hypothesized that loss of 
NHERF1 through the inhibition of E2 signaling could lead to increased Wnt/β-catenin signaling 
and endocrine resistance. To test this hypothesis, we determined NHERF1 expression and 
sensitivity to the β-catenin inhibitor ICG-001 in endocrine sensitive (MCF-7 parental) and 
endocrine resistant (LTED, TamR, LY2) cell lines.  Initial studies indicated that the proliferation 
of endocrine resistant cell lines was significantly inhibited by ICG-001, while endocrine 
sensitive cells were not affected.  
Our results indicate that acute deprivation of E2 in parental MCF-7s significantly reduced 
NHERF1 expression, consistent with previous reports from independent groups [162]. 
Unexpectedly, the endocrine resistant cell lines expressed NHERF1 at levels comparable to those 
of the parental cell lines cultured in the presence of excess E2. Human IHC results indicated that 
at least in some cases chronic anti-estrogen treatment can decrease NHERF1 expression, yet in 
other cases NHERF1 expression increases or stays the same. One explanation for this 
discrepancy between acute and chronic estrogen deprivation is that over time cells may increase 
NHERF1 expression through non-E2 mediated signaling pathways.  In colon cells, mTOR 
inhibition by rapamycin significantly decreased NHERF1 expression [326].  The mechanistic 
target of rapamycin (mTOR) is an atypical S/T kinase that functions downstream of many 
different signaling pathways, including growth factors, hormones and cytokines [352]. NFκB 
signaling has also been shown to increase NHERF1 expression [325].  As mentioned in chapter 
1, ERα can inhibit NFκB signaling in the nucleus. Therefore, it is possible that the decrease of 
NHERF1 expression caused by loss of ERα signaling is compensated by increases in NFκB 
activation.  Others have reported increased NFκB signaling in estrogen receptor negative breast 
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cancer cells, further supporting this hypothesis [220]. However, more evidence is needed to 
determine the factors that increase NHERF1 expression in estrogen-independent MCF-7 derived 
cell lines.  
Later experiments revealed that ICG-001 inhibits the growth of some endocrine sensitive 
breast cancer cell lines, parental T47Ds and MCF-7 ATCC cells, despite the presence of 
estrogen. Additionally, no significant differences in β-catenin phosphorylation status and 
expression could be found between endocrine sensitive and endocrine resistant MCF-7 cells.  It 
is possible that in breast cancer cells in culture β-catenin transcription contributes to cell 
proliferation in the presence of estrogen, but it is not always needed, explaining the lack of 
correlation between endocrine resistance and ICG-001 sensitivity.  Another confounding factor is 
the fact that one of the main differences between the MCF-7 and MCF-7 ATCC cell lines used 
was the initial passage number (155 vs 51 respectively), which could have contributed to the 
differences seen in our studies. Different culturing conditions between laboratories, cell line 
passage number, and a lack of authentication of cell lines often leads to conflicting results for the 
same assay [353]. For example, MCF-7s cultured in different laboratories have been reported to 
have a wide range of sensitivity to estrogen and different growth rates [354, 355].  Indeed, 
misidentification of cell lines and other factors that contribute to the differences between 
theoretically identical cell lines have been recognized as a major issue in scientific research 
[356]. 
The results from our study demonstrated that Wnt conditioned media inhibits raloxifene 
but not toremifene induced growth arrest. Acute toremifene treatment did not significantly 
reduce NHERF1 expression, yet high concentrations of raloxifene reduced NHERF1 by over 
60%.  However, one of the characteristic features of SERMs is their ability to assert different 
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signaling effects depending on the target tissues and context of ERα co-regulators [357]. Recent 
proteomic studies revealed that tamoxifen, raloxifene and fulvestrant have significant differences 
in their regulation of ERα-cofactor interactions [358], however more evidence is needed to 
determine the mechanism behind the observed differences between raloxifene and toremifene 
Wnt rescue.   
Although the role of NHERF1 and Wnt/β-catenin signaling in breast cancer progression 
remains unclear, several strides have been made in understanding the role of NHERF1 in 
Wnt/PCP signaling in the ependyma. Our studies confirmed the presence of a hydrocephalus 
phenotype in NHERF1 knock out mice that was originally reported in 2002.  We determined that 
NHERF1 knockout mice developed a form of communicating hydrocephalus characterized by 
reduced ciliogenesis and random organization of cilial bodies in the ependymal tissues.  
Furthermore, we showed that NHERF1 knockdown in zebrafish also leads to hydrocephalus, 
demonstrating that NHERF1 expression can regulate motile cilia function in more than one 
species. Since NHERF1 is excluded from the cilia structure, we hypothesized that the 
phenotypes associated with loss of NHERF1could be due to deregulation of the Wnt PCP 
pathway.  As reviewed in chapter 1, Wnt PCP signaling has been linked to ciliogeneisis and cilia 
organization by several independent groups, and mice lacking expression of the PCP proteins 
Celsr2 and Celsr3 show a similar hydrocephalus phenotype. This hypothesis was further 
supported by the observation that NHERF1 knockdown in zebrafish presented tail deformities 
similar to those of the Wnt5a/pipetail phenotype in zebrafish and reminiscent of the 
characteristic phenotype of Vangl Looptail mutants in mice.  
Further evidence that NHERF1 could potentially regulate Wnt PCP signaling came from 
the observation that NHERF1 knockout mice lacked Vangl2 expression at the apical surface of 
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the ependyma.  Vangl1 & Vangl2 both possess class I PDZ ligands at their C-termini that can 
mediate interactions the PDZ domains of NHERF1. Our results indicate that NHERF1 interacts 
with Vangl receptors and promotes their plasma membrane localization.  Furthermore, mutation 
of Vangl C-terminal PDZ ligands results in loss of Vangl plasma membrane subcellular 
localization. Vangl proteins can also interact with other PDZ scaffolds, including PSD-95 and 
MAGI-3 [351, 359].  Studies have shown that accumulation of Vangl2 at the plasma membrane 
during certain stages of gastrulation is crucial for initiating convergent extension in zebrafish, 
and that Vangl2 subcellular localization is dynamic and highly regulated [360]. These results are 
consistent with several studies that implicate PDZs in the maintenance of apical-basal polarity. 
PDZ proteins themselves are polarized in their distribution, and specific PDZ domain containing 
proteins are rarely found on both apical and basolateral membranes [361].  PDZs are also 
required for the plasma membrane targeting of their targets.  PDZs are involved in the trafficking 
and sorting of their binding partners, as well as retaining their targets in their final destination 
[33, 361, 362]. If PDZs themselves are polarized, than it stands to reason that a primary function 
of PDZs is to properly localize their targets to either apical or basolateral membranes, thereby 
aiding in the maintenance of apical-basal polarity [361].   
PDZs also have more active functions in the determination of polarity. Scribble is a PDZ 
domain containing scaffold that has also been reported to interact with PCP proteins and regulate 
their signaling [363, 364].  Scribble is located at septate junctions on the lateral plasma 
membrane of epithelial cells, right at the apical-basal border. Scribble regulates apical-basal 
polarity in Drosophila and loss of the protein leads to severe defects [365].  Vangl and Scribble 
have been shown to interact genetically in Drosophila and bind directly in vitro. Although 
Scribble is not required for the apical localization of Stbm (Vangl homolog), mutation of 
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Scribble at the Scribble-Stbm interaction domain results in PCP defects [366]. The authors of 
this study hypothesize that Scribble could act as a downstream PCP effector, but it is also 
possible that Scribble is required for the asymmetric distribution of other components of PCP 
signaling.  Indeed, planar polarity cannot be achieved if core PCP components are not 
asymmetrically expressed and they rely on each other for proper localization [367]. 
Aside from their function in trafficking and localization, PDZ proteins act as critical 
scaffolds in cell signaling [368]. Studies in cell culture models indicated that NHERF1 
expression induces the association of Vangl2 with Fzd receptors, and that this function requires 
both PDZ domains of the scaffold.   The PDZ domain containing scaffold MAGI-3 has also been 
shown to induce the formation of Fzd-Vangl complexes, suggesting that PDZ scaffolds could be 
crucial for the regulation of Wnt PCP signaling complexes [351].  Given that NHERF1 knockout 
mice also presented increased nuclear β-catenin in the ependyma, these results portray NHERF1 
as a master regulator of Wnt signaling in the mouse ependyma.  We propose that NHERF1 may 
function as a molecular switch between the two pathways, inducing complexes that favor Wnt 
PCP signaling at the expense of β-catenin activation.  This model is further supported by the 
observation that NHERF1 knockout in mice reduces cilia number, a phenotype not associated 
with Vangl knockouts. This difference can be explained by the fact that increased levels of β-
catenin reduce tubulin acetylation and impair cilia formation, further supporting the model that 
NHERF1 regulates both canonical and non-canonical signaling [346].   
Many of the Wnt signaling components contain C-terminal PDZ ligands: 8 of the 10 Fzd 
receptors (all except Fzd3 and Fzd6), Vangl1/2 and β-catenin.  Furthermore, Dvl contains a PDZ 
domain which mediates its’ interaction with Fzd receptors.  Dvl mediates both Wnt/β-catenin 
and Wnt PCP signaling, raising the question of how Dvl “decides” which pathway to activate.  
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So far the evidence suggests that the initial events that determine which pathway is activated are 
mediated by the formation of protein complexes at the plasma membrane. Wnt/β-catenin 
signaling is initiated by the formation of protein complexes termed signalosomes that contain 
Fzd and LRP5/6 receptors [369].  Preceding PCP signaling events in Drosophila, two complexes 
are located on opposite sides of the plasma membrane; Fz-Dsh-Dgo complex localized distally 
and Stbm-Pk localized proximally, the interaction between distal and proximal PCP components 
in adjacent cells then propagates the PCP signal along the tissue [369].  In zebrafish, the protein 
Rack1 is required for plasma membrane localization of Vangl2, and its expression antagonizes 
Wnt/β-catenin signaling [370].  In this way, factors that favor the formation of Wnt PCP 
complexes seem to simultaneously decrease the activation of Wnt canonical signaling.  This 
suggests that certain protein complexes are formed at the expense of others, consistent with our 
data.  
We conclude that NHERF1 aids in the plasma membrane targeting of Vangl proteins in 
certain epithelial tissues, and that it further acts as a scaffold for Wnt PCP signaling complexes. 
Binding of NHERF1 to Fzd receptors increases Fzd-Vangl association and results in reduced β-
catenin activation.  The lack of a global phenotype indicative of Wnt dysfunction in NHERF1 
knock out mice suggests that the function of the scaffold is redundant in certain contexts.  This 
implies a general function for PDZ proteins in the regulation of Wnt-signaling complexes and 
establishment of polarity.  
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